Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Mar. 31, 2018	May 04, 2018	Sep. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	Prestige Brands Holdings, Inc.
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		53,073,534
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 2,651.0

Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Revenues
Net sales	$ 1,040,792	$ 881,113	$ 803,088
Other revenues	387	947	3,159
Total revenues	1,041,179	882,060	806,247
Cost of Sales
Cost of sales excluding depreciation	459,676	381,333	339,036
Cost of sales depreciation	4,998	441	0
Cost of sales	464,674	381,774	339,036
Gross profit	576,505	500,286	467,211
Operating Expenses
Advertising and promotion	147,286	128,359	110,802
General and administrative	85,001	89,143	72,418
Depreciation and amortization	28,428	25,351	23,676
Loss on divestitures	0	51,820	0
Tradename impairment	99,924	0	0
Total operating expenses	360,639	294,673	206,896
Operating income	215,866	205,613	260,315
Other (income) expense
Interest income	(388)	(203)	(162)
Interest expense	106,267	93,546	85,322
Loss on extinguishment of debt	2,901	1,420	17,970
Total other (income) expense	108,780	94,763	103,130
Income before income taxes	107,086	110,850	157,185
(Benefit) provision for income taxes	(232,484)	41,455	57,278
Net income	$ 339,570	$ 69,395	$ 99,907
Earnings per share:
Basic (in USD per share)	$ 6.40	$ 1.31	$ 1.89
Diluted (in USD per share)	$ 6.34	$ 1.30	$ 1.88
Weighted average shares outstanding:
Basic (in shares)	53,099	52,976	52,754
Diluted (in shares)	53,526	53,362	53,143
Comprehensive income (loss), net of tax:
Currency translation adjustments	$ 5,702	$ (2,575)	$ (113)
Unrecognized net gain (loss) on pension plans	1,335	(252)	0
Total other comprehensive income (loss)	7,037	(2,827)	(113)
Comprehensive (loss) income	$ 346,607	$ 66,568	$ 99,794

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Current assets
Cash and cash equivalents	$ 32,548	$ 41,855
Accounts receivable, net of allowance of $12,734 and $13,010, respectively	140,881	136,742
Inventories	118,547	115,609
Deferred income tax assets	26	0
Prepaid expenses and other current assets	11,475	40,228
Total current assets	303,477	334,434
Property, plant and equipment, net	52,552	50,595
Goodwill	620,098	615,252
Intangible assets, net	2,780,916	2,903,613
Other long-term assets	3,569	7,454
Total Assets	3,760,612	3,911,348
Current liabilities
Accounts payable	61,390	70,218
Accrued interest payable	9,708	8,130
Other accrued liabilities	52,101	83,661
Total current liabilities	123,199	162,009
Long-term debt
Principal amount	2,013,000	2,222,000
Less unamortized debt costs	(20,048)	(28,268)
Long-term debt, net	1,992,952	2,193,732
Deferred income tax liabilities	442,518	715,086
Other long-term liabilities	23,333	17,972
Total Liabilities	2,582,002	3,088,799
Commitments and Contingencies – Note 17
Stockholders’ Equity
Preferred stock – $0.01 par value; Authorized – 5,000 shares; Issued and outstanding – None	0	0
Common stock – $0.01 par value; Authorized – 250,000 shares; Issued – 53,396 shares and 53,287 shares at March 31, 2018 and 2017, respectively	534	533
Additional paid-in capital	468,783	458,255
Treasury stock, at cost – 353 shares at March 31, 2018 and 332 shares at March 31, 2017	(7,669)	(6,594)
Accumulated other comprehensive loss, net of tax	(19,315)	(26,352)
Retained earnings	736,277	396,707
Total Stockholders’ Equity	1,178,610	822,549
Total Liabilities and Stockholders’ Equity	$ 3,760,612	$ 3,911,348

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Statement of Financial Position [Abstract]
Allowance for accounts receivable	$ 12,734	$ 13,010
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	53,396,000	53,287,000
Treasury stock (in shares)	353,000	332,000

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive (Loss) Income	Retained Earnings (Accumulated Deficit)
Balances at Mar. 31, 2015	$ 627,624	$ 525	$ 426,584	$ (3,478)	$ (23,412)	$ 227,405
Common stock (in shares) at Mar. 31, 2015		52,562,000
Treasury stock (in shares) at Mar. 31, 2015				266,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	9,954		9,954
Exercise of stock options	$ 6,688	$ 3	6,685
Exercise of stock options (in shares)	348,000	348,000
Issuance of shares related to restricted stock	$ 1	$ 2	(1)
Issuance of shares related to restricted stock (in shares)		156,000
Treasury share repurchases	(1,685)			$ (1,685)
Treasury share repurchases (in shares)				40,000
Excess tax benefits from share-based awards	1,960		1,960
Comprehensive (loss) income	99,794				(113)	99,907
Balances at Mar. 31, 2016	744,336	$ 530	445,182	$ (5,163)	(23,525)	327,312
Common stock (in shares) at Mar. 31, 2016		53,066,000
Treasury stock (in shares) at Mar. 31, 2016				306,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	8,148		8,148
Exercise of stock options	$ 4,028	$ 2	4,026
Exercise of stock options (in shares)	126,800	127,000
Issuance of shares related to restricted stock	$ 0	$ 1	(1)
Issuance of shares related to restricted stock (in shares)		94,000
Treasury share repurchases	(1,431)			$ (1,431)
Treasury share repurchases (in shares)				26,000
Excess tax benefits from share-based awards	900		900
Comprehensive (loss) income	66,568				(2,827)	69,395
Balances at Mar. 31, 2017	$ 822,549	$ 533	458,255	$ (6,594)	(26,352)	396,707
Common stock (in shares) at Mar. 31, 2017		53,287,000
Treasury stock (in shares) at Mar. 31, 2017	332,000			332,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 8,909		8,909
Exercise of stock options	$ 1,620	$ 0	1,620
Exercise of stock options (in shares)	55,700	56,000
Issuance of shares related to restricted stock	$ 0	$ 1	(1)
Issuance of shares related to restricted stock (in shares)		53,000
Treasury share repurchases	(1,075)			$ (1,075)
Treasury share repurchases (in shares)				21,000
Comprehensive (loss) income	346,607				7,037	339,570
Balances at Mar. 31, 2018	$ 1,178,610	$ 534	$ 468,783	$ (7,669)	$ (19,315)	$ 736,277
Common stock (in shares) at Mar. 31, 2018		53,396,000
Treasury stock (in shares) at Mar. 31, 2018	353,000			353,000

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Operating Activities
Net income	$ 339,570	$ 69,395	$ 99,907
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	33,426	25,792	23,676
Loss on divestitures	0	51,820	0
Loss (gain) on sale or disposal of property and equipment	1,568	573	(35)
Deferred income taxes	(269,086)	(5,778)	46,152
Long term income taxes payable	0	581	(332)
Amortization of debt origination costs	6,742	8,633	8,994
Excess tax benefits from share-based awards	0	900	1,960
Stock-based compensation costs	8,909	8,148	9,954
Loss on extinguishment of debt	2,901	1,420	17,970
Premium payment on 2012 Senior Notes	0	0	(10,158)
Impairment loss	99,924	0	0
Lease termination costs	214	524	0
Other non-cash items	1,704	0	0
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(5,043)	(18,938)	1,824
Inventories	(2,482)	(10,262)	(3,005)
Prepaid expenses and other assets	33,721	(1,996)	(7,921)
Accounts payable	(10,028)	21,447	(11,348)
Accrued liabilities	(31,495)	2,413	(1,328)
Pension and deferred compensation contribution	(435)	(6,000)	0
Net cash provided by operating activities	210,110	148,672	176,310
Investing Activities
Purchases of property, plant and equipment	(12,532)	(2,977)	(3,568)
Proceeds from divestitures	0	110,717	0
Proceeds from the sale of property, plant and equipment	0	85	344
Proceeds from working capital arbitration settlement	0	1,419	7,237
Acquisition of DenTek, less cash acquired	0	0	(226,984)
Acquisition of C.B. Fleet, less cash acquired	0	(803,839)	0
Acquisition of Fleet escrow receipt	970	0	0
Net cash used in investing activities	(11,562)	(694,595)	(222,971)
Financing Activities
Proceeds from issuance of 2016 Senior Notes	250,000	0	350,000
Repayment of 2012 Senior Notes	0	0	(250,000)
Borrowings under Bridge term loans	0	0	80,000
Repayments under Bridge term loans	0	0	(80,000)
Proceeds from issuance of Term Loan	0	1,427,000	0
Term Loan repayments	(444,000)	(862,500)	(60,000)
Borrowings under revolving credit agreement	30,000	110,000	115,000
Repayments under revolving credit agreement	(45,000)	(105,000)	(96,100)
Payments of debt origination costs	(500)	(11,140)	(11,828)
Proceeds from exercise of stock options	1,620	4,028	6,689
Proceeds from restricted stock exercises	0	0	544
Fair value of shares surrendered as payment of tax withholding	(1,075)	(1,431)	(2,229)
Net cash (used in) provided by financing activities	(208,955)	560,957	52,076
Effects of exchange rate changes on cash and cash equivalents	1,100	(409)	497
(Decrease) increase in cash and cash equivalents	(9,307)	14,625	5,912
Cash and cash equivalents - beginning of year	41,855	27,230	21,318
Cash and cash equivalents - end of year	32,548	41,855	27,230
Interest paid	98,572	85,209	79,132
Income taxes paid	$ 24,440	$ 47,999	$ 15,352

Business and Basis of Presentation

12 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business and Basis of Presentation

Nature of Business

Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers and drug, food, dollar, convenience, and club stores in North America (the United States and Canada) and in Australia and certain other international markets. Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 10 to these Consolidated Financial Statements.

Basis of Presentation

Our Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). All significant intercompany transactions and balances have been eliminated in consolidation. Our fiscal year ends on March 31st of each year. References in these Consolidated Financial Statements or notes to a year (e.g., “2018”) mean our fiscal year ended on March 31st of that year.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances and inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.

Reclassification

In accordance with Accounting Standards Update (“ASU”) 2016-09, Compensation - Stock Compensation (Topic 718), we have reclassified cash flows on our Condensed Consolidated Statements of Cash Flows related to excess tax benefits from a financing activity to an operating activity for all periods presented. The impact of the reclassification on our Financial Statements was not material.

Cash and Cash Equivalents

We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. At March 31, 2018, approximately 23% of our cash is held by a bank in Sydney, Australia. Substantially all of our remaining cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insures our domestic balances, up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at March 31, 2018 are uninsured. We had non-cash financing activities in 2018 of $0.6 million relating to the March 2018 debt refinancing (see Note 10 for further details).

Accounts Receivable

We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers’ financial condition, (iii) monitor the payment history and aging of customers’ receivables, and (iv) monitor open orders against an individual customer’s outstanding receivable balance.

Inventories

Inventories are stated at the lower of cost or net realizable value, where cost is determined by using the first-in, first-out method. We reduce inventories for the diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated net realizable value. Factors utilized in the determination of estimated net realizable value include (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

Property, Plant and Equipment

Property, plant and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Building	15 - 40
Machinery	3 - 15
Computer equipment and software	3 - 5
Furniture and fixtures	7 - 10
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.

Property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Goodwill

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the product group level, which is one level below the operating segment level.

Intangible Assets

Intangible assets, which are comprised primarily of tradenames, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives, typically ranging from 10 to 30 years.

Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amount may exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Debt Origination Costs

We have incurred debt origination costs in connection with the issuance of long-term debt. These costs are amortized over the term of the related debt, using the effective interest method for our bonds and our term loan facility and the straight-line method for our revolving credit facility. Costs associated with our revolving credit facility are reported as a long-term asset and costs related to our senior notes and the term loan facility are recorded as a reduction of debt.

Revenue Recognition

Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) the selling price is fixed or determinable; (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when product is received by the customer and, accordingly, we recognize revenue at that time. Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of the promotional program, the estimated amounts are adjusted to actual results.

Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

Cost of Sales

Cost of sales includes costs related to the manufacture of our products, including raw materials, direct labor and indirect plant costs (including but not limited to depreciation), warehousing costs, inbound and outbound shipping costs, and handling and storage costs. Warehousing, shipping and handling and storage costs were $64.7 million for 2018, $46.2 million for 2017 and $39.2 million for 2016.

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred. Allowances for distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these slotting fee distribution arrangements, the retailers allow our products to be placed on the stores’ shelves in exchange for such fees.

Stock-based Compensation

We recognize stock-based compensation expense by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period.

Pension Expense

Certain employees of C.B. Fleet Company, Inc. ("Fleet") are covered by defined benefit pension plans. The Company’s policy is to contribute at least the minimum amount required under The Employee Retirement Income Security Act of 1974 ("ERISA"). The Company may elect to make additional contributions. Benefits are based on years of service and levels of compensation. On December 16, 2014, the decision was made to freeze the benefits under the Company's U.S. qualified defined benefit pension plan with an effective date of March 1, 2015.

The funded status of our pension plans is dependent upon many factors, including returns on invested assets and the level of certain market interest rates. We review pension assumptions regularly and we may from time to time make voluntary contributions to our pension plans that exceed the amounts required by statute. Changes in interest rates and the market value of the securities held by the plans could materially change, positively or negatively, the funded status of the plans and affect the level of pension expense and required contributions in fiscal 2019 and beyond.

Income Taxes

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act ("Tax Act"). The Tax Act represents significant U.S. federal tax reform legislation that includes a permanent reduction to the U.S. federal corporate income tax rate. The permanent reduction to the federal corporate income tax rate resulted in a one-time gain of $267.0 million related to the value of our deferred tax liabilities and a gain of $3.2 million related to the lower blended tax rate on our current year earnings, resulting in a net gain of $270.2 million. Additionally, the tax reform legislation subjects certain of our cumulative foreign earnings and profits to U.S. income taxes through a deemed repatriation, which resulted in a charge of $1.9 million during 2018.

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied such guidance in determining our tax uncertainties.

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Basic earnings per share is computed based on income available to common stockholders and the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on income available to common stockholders and the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options and restricted stock units ("RSUs"). Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options and unvested RSUs, are included in the diluted earnings per share calculation to the extent that they are dilutive. In loss periods, the assumed exercise of in-the-money stock options and RSUs has an antidilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share. The following table sets forth the computation of basic and diluted earnings per share:



	Year Ended March 31,
(In thousands, except per share data)	2018		2017		2016
Numerator
Net income	$	339,570	$	69,395	$	99,907

Denominator
Denominator for basic earnings per share - weighted average shares outstanding	53,099		52,976		52,754
Dilutive effect of unvested restricted stock units and options issued to employees and directors	427		386		389
Denominator for diluted earnings per share	53,526		53,362		53,143

Earnings per Common Share:
Basic net earnings per share	$	6.40	$	1.31	$	1.89

Diluted net earnings per share	$	6.34	$	1.30	$	1.88

For 2018, 2017, and 2016 there were 0.4 million, 0.2 million, and less than 0.1 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

Recently Adopted Accounting Pronouncements

In March 2018, the FASB issued ASU 2018-05, Income Taxes (Topic 740). The amendments in this update reflect the income tax accounting implications of the Tax Act. See "Income Taxes" above for a discussion of the Tax Act that was signed into law on December 22, 2017, and the impact it has had and may have on our business and financial results.

In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The amendments in this update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act. See "Income Taxes" above for a discussion of the Tax Act that was signed into law on December 22, 2017, and the impact it has had and may have on our business and financial results. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. We have early adopted ASU 2018-02 and the adoption did not have a material impact on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in this update involve several aspects of accounting for share-based payment transactions, including income tax consequences, classification of awards and classification on the statement of cash flows. For public business entities, the amendments in this update were effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We adopted ASU 2016-09 effective April 1, 2017, and the adoption did not have a material impact on our consolidated financial statements.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory. The amendments in this update more closely align the measurement of inventory in GAAP with the measurement of inventory in International Financial Reporting Standards, under which an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public business entities, the amendments were effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Our adoption of ASU 2015-11, effective April 1, 2017, did not have a material impact on our consolidated financial statements.

Recently Issued Accounting Pronouncements

In March 2017, the FASB issued ASU 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, which changes the presentation of net periodic benefit cost related to employer sponsored defined benefit plans and other postretirement benefits. Service cost should be included in the same income statement line item as other compensation costs arising from services rendered during the period, while other components of net periodic benefit pension cost should be presented separately outside of operating income. Additionally, only service costs may be capitalized in assets. Entities should apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. The guidance limiting the capitalization of net periodic benefit cost in assets to the service cost component should be applied prospectively. The standard is effective for annual reporting periods beginning after December 15, 2017. The adoption of this standard will require us to move certain pension costs out of operating income.

In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We are evaluating the impact of adopting this guidance on our consolidated financial statements and whether to early adopt this ASU.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805); Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business to help companies evaluate whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. We will adopt this standard as of the beginning of our fiscal 2019, and we do not expect a material impact to our consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments. The amendments in this update provide clarification and guidance on eight cash flow classification issues. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. We will adopt this standard as of the beginning of our fiscal 2019, and we do not expect a material impact to our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases. The amendments in this update include a new FASB ASC Topic 842, which supersedes Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. We are evaluating the impact of adopting this guidance on our consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606, including new FASB ASC 606, which supersedes the revenue recognition requirements in FASB ASC 605. Along with amendments issued in 2015 and 2016, the new guidance will eliminate industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue. The core principle of the new guidance is that an entity should recognize revenue for the transfer of goods and services equal to an amount it expects to be entitled to receive for those goods and services. The new standard will also require additional disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The new guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively by recognizing the cumulative effect of initially applying the guidance to all contracts existing at the date of initial application (the modified retrospective method). The ASU, as amended, is effective for annual reporting periods beginning after December 15, 2017.

Our implementation approach included performing a detailed study of the various types of agreements that we have with our customers and assessed conformance of our current accounting practices with the new standard. We will adopt the guidance effective on April 1, 2018 using the modified retrospective method. We are finalizing the accounting policies under the new guidance and determined it may impact the timing of revenue recognition for product sales and the timing of revenue reductions associated with certain customer promotional programs we participate in.

Acquisitions

12 Months Ended

Mar. 31, 2018

Business Combinations [Abstract]

Acquisitions

The following acquisitions were accounted for in accordance with Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

Acquisition of Fleet

On January 26, 2017, the Company completed the acquisition of Fleet pursuant to the Agreement and Plan of Merger, dated as of December 22, 2016, for $823.7 million plus cash on hand at closing and subject to certain adjustments related to net working capital. The purchase price was funded by available cash on hand, additional borrowings under our asset-based revolving credit facility, and a new $740.0 million senior secured incremental term loan under the 2012 Term Loan. As a result of the merger, we acquired women's health, gastrointestinal and dermatological care OTC brands, including Summer’s Eve, Fleet, and Boudreaux's Butt Paste, as well as a “mix and fill” manufacturing facility in Lynchburg, Virginia. The financial results from the Fleet acquisition are included in the Company's North American and International OTC Healthcare segments.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the January 26, 2017 acquisition date:



(In thousands)	January 26, 2017

Cash	$	19,884
Accounts receivable	25,293
Inventories	20,812
Prepaid expenses and other current assets	17,024
Property, plant and equipment, net	38,661
Goodwill	273,058
Intangible assets, net	747,600
Other long-term assets	1,137
Total assets acquired	1,143,469

Accounts payable	10,412
Accrued expenses	22,895
Deferred income taxes - long term	261,555
Other long term liabilities	24,884
Total liabilities assumed	319,746
Total purchase price	$	823,723

Based on this analysis, we allocated $648.7 million to non-amortizable intangible assets and $98.9 million to amortizable intangible assets. We recorded goodwill of $273.1 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The goodwill is a result of acquiring and retaining workforces and expected synergies from integrating Fleet's operations into the Company's. Goodwill is not deductible for income tax purposes.

The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Fleet's operations been included in our operations commencing on April 1, 2015, based on available information related to Fleet's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Fleet acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results.



	Year Ended March 31,
	2017		2016
(In thousands, except per share data)	(Unaudited)
Revenues	$	1,049,473	$	1,004,698
Net income	$	73,750	$	92,712

Earnings per share:
Basic EPS	$	1.39	$	1.76

Diluted EPS	$	1.38	$	1.74

Acquisition of DenTek

On February 5, 2016, the Company completed the acquisition of DenTek Holdings, Inc. ("DenTek"), a privately-held marketer and distributor of specialty oral care products. The closing was finalized pursuant to the terms of the merger agreement, announced November 23, 2015, under which the Company agreed to acquire DenTek from its stockholders for a purchase price of $226.9 million. The acquisition expanded the Company's portfolio of brands, strengthened its existing oral care platform and increased its geographic reach in parts of Europe. The Company financed the transaction with a combination of available cash on hand, available cash from its asset based loan revolver, and financing of an additional unsecured bridge loan. The DenTek brands are included in the Company's North American and International OTC Healthcare segments.

Divestitures and Sale of License Rights	12 Months Ended
Divestitures and Sale of License Rights	Mar. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Divestitures and Sale of License Rights	Divestitures and Sale of License Rights Divestitures On July 7, 2016, we completed the sale of the Pediacare®, New Skin® and Fiber Choice® brands for $40.0 million plus the cost of inventory. During the year ended March 31, 2017, we recorded a pre-tax loss on sale of $56.2 million. The proceeds were used to repay debt and related income taxes due on the dispositions. Concurrent with the completion of the sale of these brands, we entered into an option agreement with the buyer to purchase Dermoplast® at a specified earnings multiple as defined in the option agreement. The buyer paid a $1.25 million deposit for this option in September 2016 and later notified us of its election to exercise the option. In December 2016, we completed the sale of the Dermoplast® brand, and in a separate transaction, the e.p.t® brand, for an aggregate amount of $59.6 million. As a result, we recorded a pre-tax net gain on these divestitures of $3.9 million. Sale of license rights Historically, we received royalty income from the licensing of the names of certain of our brands in geographic areas or markets in which we do not directly compete. We have had royalty agreements for our Comet brand for several years, which included options on behalf of the licensee to purchase license rights in certain geographic areas and markets in perpetuity. In December 2014, we amended these agreements, and we sold rights to use of the Comet brand in certain Eastern European countries to a third-party licensee in exchange for $10.0 million as a partial early buyout of the license. The amended agreement provided that we would continue to receive royalty payments of $1.0 million per quarter for the remaining geographic areas and also granted the licensee an option to acquire the license rights in the remaining geographic areas any time after June 30, 2016. In July 2016, the licensee elected to exercise its option. In August 2016, we received $11.0 million for the purchase of the remaining license rights and, as a result, we recorded a pre-tax gain of $1.2 million and reduced our indefinite-lived tradenames by $9.0 million. Furthermore, the licensee was no longer required to make additional royalty payments to us, and as a result, our royalty income was reduced accordingly.

Accounts Receivable

12 Months Ended

Mar. 31, 2018

Receivables [Abstract]

Accounts Receivable

Accounts receivable consist of the following:



	March 31,
(In thousands)	2018			2017
Components of Accounts Receivable
Trade accounts receivable	$	152,832		$	148,339
Other receivables	783			1,413
	153,615			149,752
Less allowances for discounts, returns and uncollectible accounts	(12,734		)	(13,010		)
Accounts receivable, net	$	140,881		$	136,742

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Property, Plant and Equipment

12 Months Ended

Mar. 31, 2018

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant and equipment, net consist of the following:



	March 31,
(In thousands)	2018			2017
Components of Property, Plant and Equipment
Land	$	550		$	550
Building	13,746			13,156
Machinery	38,599			31,456
Computer equipment	18,116			15,440
Furniture and fixtures	2,924			2,720
Leasehold improvements	8,804			7,497
	82,739			70,819
Accumulated depreciation	(30,187		)	(20,224		)
Property, plant and equipment, net	$	52,552		$	50,595

We recorded depreciation expense of $10.1 million, $6.0 million, and $5.2 million for 2018, 2017, and 2016, respectively.

Goodwill

12 Months Ended

Mar. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

The following table summarizes the changes in the carrying value of goodwill by operating segment for each of 2016, 2017, and 2018:



(In thousands)	North American OTC Healthcare			International OTC Healthcare			Household Cleaning			Consolidated
Balance – March 31, 2016	$	330,615		$	22,776		$	6,800		$	360,191

2017 additions	258,438			10,139			—			268,577
2017 reductions	(12,600		)	—			(555		)	(13,155		)
Effects of foreign currency exchange rates	—			(361		)	—			(361		)

Balance – March 31, 2017	576,453			32,554			6,245			615,252

2018 adjustments ^(a)	4,481			—			—			4,481
Effects of foreign currency exchange rates	—			365			—			365

Balance – March 31, 2018	$	580,934		$	32,919		$	6,245		$	620,098

(a) Amount relates to a measurement period adjustment recorded during 2018, associated with our Fleet acquisition.

As further discussed in Note 8, in December 2014, we completed a transaction to sell rights to use of the Comet brand in certain Eastern European countries to a third-party licensee. As a result, we recorded a gain on the sale of $1.3 million and reduced the carrying value of our intangible assets and goodwill. In August 2016, we sold the remaining rights to the use of the Comet brand in certain geographic areas and reduced goodwill by $0.6 million as a result.

As discussed in Note 2, on February 5, 2016, we completed the acquisition of DenTek. In connection with this acquisition, we recorded goodwill of $73.7 million based on the amount by which the purchase price exceeded the fair value of net assets acquired. In December 2016, we received $1.4 million as a result of an arbitration associated with the DenTek acquisition. As a result, we reduced goodwill by $2.8 million, including other post-closing adjustments of $1.4 million.

As discussed in Note 2, on January 26, 2017, we completed the acquisition of Fleet. In connection with this acquisition, we recorded goodwill of $273.1 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired.

On July 7, 2016, we completed the sale of Pediacare®, New Skin® and Fiber Choice® (see Note 3 above for further details) for $40.0 million plus the cost of inventory and reduced goodwill by $2.9 million as a result. In addition, as discussed in Note 3, in connection with this sale, the buyer exercised its option to purchase the Dermoplast® brand. The sale of Dermoplast® was completed on December 30, 2016 and, as a result, we reduced goodwill by $5.5 million.

On December 28, 2016, we completed the sale of the e.p.t® brand and, as a result, we reduced goodwill by $1.4 million.

Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount. At February 28, 2018 and February 29, 2017, in conjunction with the annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in 2018 or 2017.

We identify our reporting units in accordance with the FASB ASC Subtopic 280. The carrying value and fair value for intangible assets and goodwill for a reporting unit are calculated based on key assumptions and valuation methodologies previously discussed. The discounted cash flow methodology is a widely-accepted valuation technique utilized by market participants in the transaction evaluation process and has been applied consistently. We also considered our market capitalization at February 28, 2018 and February 29, 2017, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future.

As a result of our analysis at February 28, 2018, all reporting units tested had a fair value that exceeded their carrying value by at least 19%.

Intangible Assets

12 Months Ended

Mar. 31, 2018

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Intangible Assets

A reconciliation of the activity affecting intangible assets, net for each of 2018 and 2017 is as follows:



	Year Ended March 31, 2018
(In thousands)	Indefinite Lived Tradenames			Finite Lived Tradenames and Customer Relationships			Totals
Gross Amount
Balance – March 31, 2017	$	2,589,155		$	441,801		$	3,030,956
Tradename impairment	(99,300		)	(624		)	(99,924		)
Effects of foreign currency exchange rates	448			137			585
Balance – March 31, 2018	$	2,490,303		$	441,314		$	2,931,617

Accumulated Amortization
Balance – March 31, 2017	$	—		$	127,343		$	127,343
Additions	—			23,349			23,349
Effects of foreign currency exchange rates	—			9			9
Balance – March 31, 2018	$	—		$	150,701		$	150,701

Intangible assets, net – March 31, 2018	$	2,490,303		$	290,613		$	2,780,916

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,375,736		$	265,356		$	2,641,092
International OTC Healthcare	84,006			6,068			90,074
Household Cleaning	30,561			19,189			49,750
Intangible assets, net – March 31, 2018	$	2,490,303		$	290,613		$	2,780,916



	Year Ended March 31, 2017
(In thousands)	Indefinite Lived Tradenames			Finite Lived Tradenames and Customer Relationships			Totals
Gross Amount
Balance – March 31, 2016	$	2,020,046		$	417,880		$	2,437,926
Additions	648,700			98,900			747,600
Reclassifications	(2,064		)	2,064			—
Reductions	(77,248		)	(76,903		)	(154,151		)
Effects of foreign currency exchange rates	(279		)	(140		)	(419		)
Balance – March 31, 2017	$	2,589,155		$	441,801		$	3,030,956

Accumulated Amortization
Balance – March 31, 2016	$	—		$	115,203		$	115,203
Additions	—			19,753			19,753
Reductions	—			(7,610		)	(7,610		)
Effects of foreign currency exchange rates	—			(3		)	(3		)
Balance – March 31, 2017	$	—		$	127,343		$	127,343

Intangible assets, net – March 31, 2017	$	2,589,155		$	314,458		$	2,903,613

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,404,336		$	287,056		$	2,691,392
International OTC Healthcare	83,558			6,468			90,026
Household Cleaning	101,261			20,934			122,195
Intangible assets, net – March 31, 2017	$	2,589,155		$	314,458		$	2,903,613

As discussed in Note 2, on February 5, 2016, we completed the acquisition of DenTek. In connection with this acquisition, we allocated $206.7 million to intangible assets based on our analysis.

As discussed in Note 2, on January 26, 2017, we completed the acquisition of Fleet. In connection with this acquisition, we allocated $747.6 million to intangible assets based on our analysis.

On July 7, 2016, we completed the sale of the Pediacare®, New Skin® and Fiber Choice® (see Note 3 above for further details) brands for $40.0 million plus the cost of inventory and received $40.1 million, and reduced our indefinite and finite-lived tradenames by $37.2 million and $54.0 million, respectively. During the year ended March 31, 2017, we recorded a pre-tax loss of $56.2 million on the sale of these brands. In addition, as discussed in Note 3, in connection with this sale, the buyer exercised its option to purchase the Dermoplast® brand. The sale of Dermoplast® was completed on December 30, 2016, and we received $48.4 million. As a result, we reduced intangible assets by $31.0 million.

Historically, we received royalty income from the licensing of the names of certain of our brands in geographic areas or markets in which we do not directly compete. We have had royalty agreements for our Comet brand for several years, which included options on behalf of the licensee to purchase license rights in certain geographic areas and markets in perpetuity. In December 2014, we amended these agreements and we sold rights to use of the Comet brand in certain Eastern European countries to a third-party licensee in exchange for $10.0 million as a partial early buyout of the license. The amended agreement provided that we would continue to receive royalty payments of $1.0 million per quarter for the remaining geographic areas and also granted the licensee an option to acquire the license rights in the remaining geographic areas any time after June 30, 2016. In July 2016, the licensee elected to exercise its option. In August 2016, we received $11.0 million for the purchase of the remaining license rights and, as a result, we recorded a pre-tax gain of $1.2 million and reduced our indefinite-lived tradenames by $9.0 million. Furthermore, the licensee is no longer required to make additional royalty payments to us, and as a result, our royalty income was reduced accordingly.

In December 2016, we also completed the sale of the e.p.t brand and, as a result, we reduced intangible assets by $14.8 million.

Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.

During the fourth quarter of each fiscal year, we perform our annual impairment analysis. We utilized the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. The discount rate utilized in the analyses, as well as future cash flows, may be influenced by such factors as changes in interest rates and rates of inflation. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer preferences, technological advances or reductions in advertising and promotional expenses, we may be required to record impairment charges in the future.

As a result of our analysis at February 28, 2018, two of our indefinite-lived intangible assets, Beano and Comet, did not exceed the carrying values and as such, impairment charges of $28.6 million and $70.7 million, respectively, were recorded in 2018 relating to these two tradenames, bringing Beano’s indefinite-lived tradename carrying value to $49.8 million and Comet’s indefinite-lived tradename carrying value to $30.6 million.

In addition, we recorded an impairment charge on our Massengill finite-lived intangible tradename of $0.6 million bringing its carrying value to zero. The impairment charges were the result of our reassessment of the long-term sales projections for these brands during our annual planning cycle. In addition, we performed a sensitivity analysis of our weighted average cost of capital and we determined that a 50 basis point increase in the weighted average cost of capital would have resulted in an additional impairment of Beano and Comet totaling $4.2 million. Additionally, a 50 basis point decrease in the terminal growth rate used for each of the Beano and Comet tradenames would have resulted in an additional impairment of $2.3 million.

Beano and Massengill are part of our North American OTC Healthcare segment and Comet is part of our Household Cleaning segment.

The weighted average remaining life for finite-lived intangible assets at March 31, 2018 was approximately 12.5 years, and the amortization expense for the year ended March 31, 2018 was $23.3 million. At March 31, 2018, finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 30 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):



(In thousands)
Year Ending March 31,	Amount
2019	23,234
2020	23,234
2021	22,812
2022	22,389
2023	22,389
Thereafter	176,555
	$	290,613

Long-Term Debt

12 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Long-Term Debt

2012 Term Loan and 2012 ABL Revolver:

On January 31, 2012, the Borrower entered into a senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a 7-year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a 5-year maturity. In subsequent years, we have utilized portions of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $85.0 million to $135.0 million and reduced our borrowing rate on the 2012 ABL Revolver by 0.25% (discussed below). The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Borrower of $650.1 million. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.

On February 21, 2013, we entered into Amendment No. 1 ("Term Loan Amendment No. 1") to the 2012 Term Loan. Term Loan Amendment No. 1 provided for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans (the "Term B-1 Loans"). The interest rate on the Term B-1 Loans under Term Loan Amendment No. 1 was based, at our option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin. In addition, Term Loan Amendment No. 1 provided the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver.

On September 3, 2014, we entered into Amendment No. 2 ("Term Loan Amendment No. 2") to the 2012 Term Loan. Term Loan Amendment No. 2 provided for (i) the creation of a new class of Term B-2 Loans under the 2012 Term Loan (the "Term B-2 Loans") in an aggregate principal amount of $720.0 million, (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on (x) the Term B-1 Loans that was based, at our option, on a LIBOR rate plus a margin of 3.125% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin, and (y) the Term B-2 Loans that was based, at our option, on a LIBOR rate plus a margin of 3.50% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio).

Also on September 3, 2014, we entered into Amendment No. 3 ("ABL Amendment No. 3") to the 2012 ABL Revolver. ABL Amendment No. 3 provided for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility. Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., and (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments by an amount set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty.

On May 8, 2015, we entered into Amendment No. 3 ("Term Loan Amendment No. 3") to the 2012 Term Loan. Term Loan Amendment No. 3 provided for (i) the creation of a new class of Term B-3 Loans under the 2012 Term Loan (the "Term B-3 Loans") in an aggregate principal amount of $852.5 million, which combined the outstanding balances of the Term B-1 Loans of $207.5 million and the Term B-2 Loans of $645.0 million, and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief. The maturity date of the Term B-3 Loans remained the same as the Term B-2 Loans' original maturity date of September 3, 2021.

On June 9, 2015, we entered into Amendment No. 4 (“ABL Amendment No. 4”) to the 2012 ABL Revolver. ABL Amendment No. 4 provided for (i) a $35.0 million increase in the accordion feature under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief and (iii) extended the maturity date of the 2012 ABL Revolver to June 9, 2020, which is five years from the effective date of ABL Amendment No. 4.

In connection with the DenTek acquisition on February 5, 2016, we entered into Amendment No. 5 (“ABL Amendment No. 5”) to the 2012 ABL Revolver. ABL Amendment No. 5 temporarily suspended certain financial and related reporting covenants in the 2012 ABL Revolver until the earliest of (i) the date that was 60 calendar days following February 4, 2016, (ii) the date upon which certain of DenTek’s assets were included in the Company’s borrowing base under the 2012 ABL Revolver and (iii) the date upon which the Company received net proceeds from an offering of debt securities.

In connection with the Fleet acquisition, on January 26, 2017, we entered into Amendment No. 4 ("Term Loan Amendment No. 4") to the 2012 Term Loan. Term Loan Amendment No. 4 provided for (i) the refinancing of all of our outstanding term loans and the creation of a new class of Term B-4 Loans under the 2012 Term Loan (the "Term B-4 Loans") in an aggregate principal amount of $1,427.0 million and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief. In addition, Citibank, N.A. was succeeded by Barclays Bank PLC as administrative agent under the 2012 Term Loan.

Also on January 26, 2017, we entered into Amendment No. 6 ("ABL Amendment No. 6") to the 2012 ABL Revolver. ABL Amendment No. 6 provides for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver, (ii) an extension of the maturity date of revolving commitments to January 26, 2022, and (iii) increased flexibility under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility consistent with Term Loan Amendment No. 4. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty.

On March 21, 2018, we entered into Amendment No. 5 (“Term Loan Amendment No. 5”) to the 2012 Term Loan. Term Loan Amendment No. 5 ("Term B-5 Loans") provided for the repricing of the Term B-4 Loans under the Credit Agreement to an interest rate that is based, at our option, on a LIBOR rate plus a margin of 2.00% per annum, with a LIBOR floor of 0.00%, or an alternative base rate plus a margin of 1.00% per annum with a floor of 1.00%.

For the year ended March 31, 2018, the average interest rate on the 2012 Term Loan was 4.5%. For the year ended March 31, 2018, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 2.7%.

2013 Senior Notes:

On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.

2016 Senior Notes:

On February 19, 2016, the Borrower completed the sale of $350.0 million aggregate principal amount of 6.375% senior notes due March 1, 2024 (the “Initial Notes”), pursuant to a purchase agreement, dated February 16, 2016, among the Borrower, the guarantors party thereto (the “Guarantors”) and the initial purchasers party thereto. The 2016 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the Guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.

The 2016 Senior Notes were issued pursuant to an indenture, dated February 19, 2016 (the “Indenture”). The Indenture provides, among other things, that interest will be payable on the 2016 Senior Notes on March 1 and September 1 of each year, beginning on September 1, 2016, until their maturity date of March 1, 2024. The 2016 Senior Notes are senior unsecured obligations of the Borrower.

On March 21, 2018, we completed the sale of $250.0 million aggregate principal amount of 6.375% senior notes due 2024 (the “Additional Notes”), at an issue price of 101.0%, pursuant to a purchase agreement, dated March 16, 2018, among Prestige Brands, the guarantors party thereto and the initial purchasers party thereto. The Additional Notes are senior unsecured obligations of Prestige Brands and are guaranteed by each of Prestige Brands’ domestic subsidiaries that guarantee its obligations under the 2012 Term Loan. We used the proceeds from the issuance of the Additional Notes to repay a portion of our outstanding obligations under the 2012 Term Loan and to pay related fees and expenses. The Additional Notes will be treated as a single series with the $350.0 million aggregate principle amount of Initial Notes (the Initial Notes and, together with the Additional Notes, the “2016 Senior Notes”).

Redemptions and Restrictions:

On or after December 15, 2016, we have had the option to redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we had the option to redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions were met. Subject to certain limitations, in the event of a change of control (as defined in the indenture governing the 2013 Senior Notes), the Borrower will be required to make an offer to purchase the 2013 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2013 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

We have the option to redeem all or a portion of the 2016 Senior Notes at any time on or after March 1, 2019 at the redemption prices set forth in the Indenture, plus accrued and unpaid interest, if any. We may also redeem all or any portion of the 2016 Senior Notes at any time prior to March 1, 2019, at a price equal to 100% of the aggregate principal amount of notes redeemed, plus a "make-whole premium" calculated as set forth in the Indenture and accrued and unpaid interest, if any. In addition, before March 1, 2019, we may redeem up to 40% of the aggregate principal amount of the 2016 Senior Notes with the net proceeds of certain equity offerings, at the redemption price set forth in the Indenture, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control (as defined in the Indenture), we will be required to make an offer to purchase the 2016 Senior Notes at a price equal to 101% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

The indentures governing the 2013 Senior Notes and the 2016 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2016 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2016 Senior Notes. At March 31, 2018, we were in compliance with the covenants under our long-term indebtedness.

At March 31, 2018, we had an aggregate of $1.1 million of unamortized debt costs related to the 2012 ABL Revolver included in other long-term assets, and $20.0 million of unamortized debt costs included in long-term debt costs, the total of which is comprised of $3.7 million related to the 2013 Senior Notes, $5.0 million related to the 2016 Senior Notes, and $11.3 million related to the 2012 Term Loan.

At March 31, 2017 we had an aggregate of $1.3 million of unamortized debt costs related to the 2012 ABL Revolver included in other long-term assets, and $28.3 million of unamortized debt costs included in long-term debt costs, the total of which is comprised of $4.6 million related to the 2013 Senior Notes, $4.9 million related to the 2016 Senior Notes, and $18.8 million related to the 2012 Term Loan.

At March 31, 2018, we had $75.0 million outstanding on the 2012 ABL Revolver and a borrowing capacity of $96.6 million.

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	March 31, 2018			March 31, 2017
2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024.	$	600,000		$	350,000
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	400,000			400,000
2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.00%, or an alternate base rate plus a margin of 1.00% with a floor of 1.00% due on January 26, 2024.	938,000			1,382,000
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 26, 2022.	75,000			90,000
Total long-term debt (including current portion)	2,013,000			2,222,000
Current portion of long-term debt	—			—
Long-term debt	2,013,000			2,222,000
Less: unamortized debt costs	(20,048		)	(28,268		)
Long-term debt, net	$	1,992,952		$	2,193,732

As of March 31, 2018, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2016 Senior Notes and the 2013 Senior Notes are as follows:



(In thousands)
Year Ending March 31,	Amount
2019	$	—
2020	—
2021	—
2022	477,000
2023	9,750
Thereafter	1,526,250
	$	2,013,000

Fair Value Measurements

12 Months Ended

Mar. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.

The Fair Value Measurements and Disclosures topic of the FASB ASC 820 requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created:

Level 1 - Quoted market prices for identical instruments in active markets;

Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and

Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant.

The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2016 Senior Notes, the 2013 Senior Notes, the Term B-5 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy (see summary below detailing the carrying amounts and estimated fair values of these borrowings at March 31, 2018 and 2017).



	March 31, 2018				March 31, 2017
(In thousands)	Carrying Value		Fair Value		Carrying Value		Fair Value
2016 Senior Notes	$	600,000	$	610,500	$	350,000	$	367,500
2013 Senior Notes	400,000		402,000		400,000		409,000
2012 Term B-5 Loans	938,000		939,173		1,382,000		1,395,820
2012 ABL Revolver	75,000		75,000		90,000		90,000

At March 31, 2018 and 2017, we did not have any assets or liabilities measured in Level 1 or 3. During 2018, 2017 and 2016, there were no transfers of assets or liabilities between Levels 1, 2 and 3.

In accordance with ASU 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent), investments that are measured at fair value using net asset value ("NAV") per share as a practical expedient have not been classified in the fair value hierarchy.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Mar. 31, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on the Company's common stock through March 31, 2018. Pursuant to the provisions of various employee restricted stock awards, we repurchased 20,549 shares and 25,768 shares of restricted common stock from our employees during the years ended March 31, 2018 and 2017, respectively. The repurchases during the years ended March 31, 2018 and 2017 were at an average price of $52.33 and $55.51, respectively. All of the repurchased shares have been recorded as treasury stock.

Share-Based Compensation

12 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units ("RSUs") and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, the stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the Plan, an increase of the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any fiscal 12-month period from 1.0 million to 2.5 million shares, and an extension of the term of the Plan by ten years, to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.

During 2018, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $8.9 million and $1.8 million, respectively.

During 2017, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $8.1 million and $2.6 million, respectively.

During 2016, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $10.0 million and $3.5 million, respectively.

At March 31, 2018, there were $8.2 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management’s estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted-average period of 0.8 years. The total fair value of options and restricted shares vested during 2018, 2017, and 2016 was $6.8 million, $6.0 million and $7.0 million, respectively. Cash received from the exercise of stock options was $1.6 million during 2018, and we realized $1.1 million in tax benefits for the tax deductions resulting from RSU issuances and option exercises in 2018. Cash received from the exercise of stock options was $4.0 million during 2017, and we realized $2.0 million in tax benefits for the tax deductions resulting from RSU issuances and option exercises in 2017. Cash received from the exercise of stock options was $6.7 million during 2016, and we realized $3.6 million in tax benefits for the tax deductions from RSU issuances and option exercises in 2016. At March 31, 2018, there were 2.2 million shares available for issuance under the Plan.

On May 8, 2017, the Compensation and Talent Management Committee of our Board of Directors granted 35,593 performance units, 54,773 RSUs and stock options to acquire 182,823 shares of our common stock to certain executive officers and employees under the Plan.

Pursuant to the Plan, each of the independent members of the Board of Directors received a grant of 2,564 RSUs on August 1, 2017. The RSUs are fully vested upon receipt of the award and will be settled by delivery to the director of one share of common stock of the Company for each vested RSU promptly following the earliest of the director's (i) death, (ii) disability or (iii) the six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability.

Restricted Stock Units

Restricted stock units granted to employees under the Plan generally vest in three years, primarily upon the attainment of certain time vesting thresholds, and, in the case of performance share units, may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The RSUs provide for accelerated vesting if there is a change of control, as defined in the Plan. The RSUs granted to employees generally vest either ratably over three years or in their entirety on the three-year anniversary of the date of the grant. Upon vesting, the units will be settled in shares of our common stock. Termination of employment prior to vesting will result in forfeiture of the RSUs, unless otherwise accelerated by the Compensation and Talent Management Committee or, in the case of RSUs granted in May 2017, subject to pro-rata vesting in the event of death, disability or retirement. The RSUs granted to directors vest immediately upon grant, and will be settled by delivery to the director of one share of common stock of the Company for each vested RSU promptly following the earliest of the director's (i) death, (ii) disability or (iii) six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability.

The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant.

A summary of the Company’s RSUs granted under the Plan is presented below:



RSUs	Shares (in thousands)		Weighted-Average Grant-Date Fair Value
Vested and nonvested at March 31, 2015	362.3		$	22.74

Granted	266.1		42.41
Vested and issued	(155.6	)	18.31
Forfeited	(5.0	)	39.61
Vested and nonvested at March 31, 2016	467.8		35.22
Vested at March 31, 2016	69.8		14.76

Granted	68.4		55.44
Vested and issued	(94.7	)	28.51
Forfeited	(91.4	)	41.71
Vested and nonvested at March 31, 2017	350.1		39.29
Vested at March 31, 2017	63.4		20.12

Granted	105.8		55.61
Vested and issued	(53.3	)	34.30
Forfeited	(9.1	)	48.76
Vested and nonvested at March 31, 2018	393.5		44.13
Vested at March 31, 2018	90.5		29.88

Options

The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Except in the case of death, disability or retirement, termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination of employment, subject to the terms in the Plan.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management’s estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options.

The weighted-average grant-date fair values of the options granted during 2018, 2017, and 2016 were $21.20, $21.75, and $17.24, respectively.



	Year Ended March 31,
	2018		2017		2016
Expected volatility	35.2	%	37.8	%	40.2	%
Expected dividends	—		—		—
Expected term in years	6.0		6.0		6.0
Risk-free rate	2.2	%	1.7	%	1.7	%

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted-Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)

Outstanding at March 31, 2015	871.2		$	23.40

Granted	208.2		42.13
Exercised	(348.0	)	19.22
Forfeited or expired	(3.7	)	35.72
Outstanding at March 31, 2016	727.7		30.70

Granted	264.3		55.86
Exercised	(126.8	)	31.75
Forfeited or expired	(92.9	)	42.66
Outstanding at March 31, 2017	772.3		37.70

Granted	182.8		56.11
Exercised	(55.7	)	29.08
Forfeited or expired	(26.2	)	48.19
Outstanding at March 31, 2018	873.2		41.79		7.0	$	2,985
Exercisable at March 31, 2018	495.0		32.41		5.8	$	2,985

The aggregate intrinsic value of options exercised during 2018, 2017 and 2016 was $1.2 million, $3.2 million and $8.6 million, respectively.

Employee Retirement Plans

12 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Employee Retirement Plans

We have a defined contribution plan in which all U.S. full-time employees (excluding those employees of the recently acquired Fleet business discussed below) are eligible to participate. The participants may contribute from 1% to 70% of their compensation, as defined in the plan. We match 100% of the first 3%, plus 50% of the next 3% of each participant's base compensation with full vesting immediately. We may also make additional contributions to the plan as determined by the Board of Directors. The total expense for the defined contribution plan was less than $0.1 million for 2018.

In conjunction with the acquisition of Fleet (see Note 2), we assumed a number of additional employee retirement plans including a defined contribution plan and two defined benefit plans. All U.S. full-time employees of Fleet are eligible to participate in Fleet's defined contribution plan. The participants may contribute from 2% to 50% of their compensation, as defined in the plan. We match 100% of the first 6% of each participant's base compensation with full vesting upon entering the plan. The Company's contribution is reduced by the amount of forfeitures that occur during the year. We may also make additional contributions to the plan as determined by the Board of Directors. The total expense for the defined contribution plan was $0.8 million for 2018.

Certain employees of Fleet are covered by defined benefit pension plans. The Company’s policy is to contribute at least the minimum amount required under ERISA. The Company may elect to make additional contributions. Benefits are based on years of service and levels of compensation. On December 16, 2014, the decision was made to freeze the benefits under the Company's U.S. qualified defined benefit pension plan with an effective date of March 1, 2015.

Benefit Obligations and Plan Assets

The following table summarizes the changes in the U.S. pension plan obligations and plan assets from the date of acquisition to the end of our fiscal year, and includes a statement of the plans' funded status as of March 31, 2018 and 2017:



	Period Ended
(In thousands)	March 31, 2018			March 31, 2017
Change in benefit obligation:
Projected benefit obligation at beginning of period	$	61,714		$	61,187
Interest cost	2,529			456
Actuarial loss	800			791
Benefits paid	(3,161		)	(720		)
Projected benefit obligations at end of year	$	61,882		$	61,714

Change in plan assets:
Fair value of plan assets at beginning of period	$	47,772		$	41,560
Actual return on plan assets	5,505			854
Employer contribution	392			6,078
Benefits paid	(3,161		)	(720		)
Fair value of plan assets at end of year	$	50,508		$	47,772

Funded status at end of year	$	(11,374	)	$	(13,942	)

Amounts recognized in the balance sheet at the end of the period consist of the following:



	Period Ended
(In thousands)	March 31, 2018		March 31, 2017
Current liability	$	461	463
Long-term liability	10,913		13,479
Total	$	11,374	$	13,942

The primary components of Net Periodic Benefits consist of the following:



	Period Ended
(In thousands)	March 31, 2018			March 31, 2017
Interest cost	$	2,529		$	456
Expected return on assets	(2,901		)	(462		)
Net periodic benefit cost (income)	$	(372	)	$	(6	)

The accumulated benefit obligation, which represents benefits earned to the measurement date, was $61.9 million at March 31, 2018, and $61.7 million at March 31, 2017 and we had a net periodic benefit (income) of less than $1.0 million for 2018 and 2017.

The pension benefit amounts stated above include one pension plan that is an unfunded plan. The projected benefit obligation and accumulated benefit obligation for this unfunded plan were $5.9 million as of March 31, 2018 and $6.0 million as of March 31, 2017.

The following table includes amounts that are expected to be contributed to the plans by the Company. It reflects benefit payments that are made from the plans' assets as well as those made directly from the Company's assets and includes the participants' share of the cost, which is funded by participant contributions. The amounts in the table are actuarially determined and reflect the Company's best estimate given its current knowledge; actual amounts could be materially different.



(In thousands)	Pension Benefits
Employer contributions:
2019 (expectation) to participant benefits	$	1,461

Expected benefit payments year ending March 31,
2019	$	3,314
2020	3,386
2021	3,463
2022	3,588
2023	3,674
2024-2028	19,157

During 2018, we made no contribution to the qualified plan. During 2017, we funded $6.0 million to the plan, which was invested as described in the plan assets below.

The Company's primary investment objective for its qualified pension plan assets is to provide a source of retirement income for the plans' participants and beneficiaries. The asset allocation for the Company's funded retirement plan as of March 31, 2018 and 2017, and the target allocation by asset category are as follows:



	Percentage of Plan Assets
Asset Category	Target Allocation		March 31, 2018		March 31, 2017
Domestic large cap equities	21	%	21	%	41	%
Domestic small/mid cap equities	6		6		7
International equities	18		18		16
Balanced/asset allocation	—		—		2
Fixed income and cash	55		55		34
Total	100	%	100	%	100	%

The plan assets are invested in a diversified portfolio consisting primarily of domestic fixed income and publicly traded equity securities held within group trust funds at March 31, 2018 and pooled separate mutual funds at March 31, 2017. These assets are fair valued using NAV.

The following tables show the unrecognized actuarial loss (gain) included in accumulated other comprehensive income at March 31, 2018 and 2017, as well as the prior service cost credit and actuarial loss expected to be reclassified from accumulated other comprehensive income (loss) to retirement expense during 2019:



(In thousands)
Balances in accumulated other comprehensive loss as of March 31, 2017:
Unrecognized actuarial loss	$	399
Unrecognized prior service credit	—

Balances in accumulated other comprehensive (income) as of March 31, 2018:
Unrecognized actuarial (gain)	$	(1,407	)
Unrecognized prior service credit	—

Amounts expected to be reclassified from accumulated other comprehensive income (loss) during 2019:
Unrecognized actuarial (loss)	$	—
Unrecognized prior service credit	—

Assumptions used in determining the actuarial present value of the benefit obligation as of March 31, 2018 and 2017 were as follows:



	Period Ended
	March 31, 2018	March 31, 2017
Key assumptions:
Discount rate	3.93% to 4.07%	3.92% to 4.21%
Expected return on plan assets, net of administrative fees	6.25%	6.25%
Rate of compensation increase	—	—

The determination of the expected long-term rate of return was derived from an optimized portfolio using an asset allocation software program. The risk and return assumptions, along with the correlations between the asset classes, were entered into the program. Based on these assumptions and historical experience, the portfolio is expected to achieve a long-term rate of return of 6.25%. The investment managers engaged to manage the portfolio are expected to outperform their expected benchmarks on a relative basis over a full market cycle.

Income Taxes

12 Months Ended

Mar. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

The changes included in the Tax Act are broad and complex. The final transition impacts of the Tax Act may differ from the above estimate, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the Company has utilized to calculate the transition impacts, including impacts from changes to current year earnings estimates and foreign exchange rates of foreign subsidiaries. The U.S. Securities and Exchange Commission has issued rules that would allow for a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts. We currently anticipate finalizing and recording any resulting adjustments by the end of the measurement period.

Income before income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2018		2017		2016
United States	$	84,435	$	93,582	$	142,253
Foreign	22,651		17,268		14,932
	$	107,086	$	110,850	$	157,185

The provision for income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2018			2017			2016
Current
Federal	$	31,327		$	40,183		$	6,080
State	2,686			2,808			1,171
Foreign	5,588			4,242			3,905
Deferred
Federal	(270,796		)	(5,421		)	44,787
State	(1,240		)	(163		)	1,678
Foreign	(49		)	(194		)	(343		)
Total (benefit) provision for income taxes	$	(232,484	)	$	41,455		$	57,278

The principal components of our deferred tax balances are as follows:



	March 31,
(In thousands)	2018			2017
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$	2,806		$	5,280
Inventory capitalization	1,176			1,881
Inventory reserves	540			1,880
Net operating loss carryforwards	609			609
State income taxes	10,154			17,727
Accrued liabilities	2,210			2,174
Accrued compensation	4,992			9,574
Stock compensation	5,038			5,790
Other	4,975			7,925
Total deferred tax assets	$	32,500		$	52,840

Deferred Tax Liabilities
Property, plant and equipment	$	(6,032	)	$	(9,157	)
Intangible assets	(467,388		)	(754,322		)
Total deferred tax liabilities	$	(473,420	)	$	(763,479	)

Net deferred tax liability before valuation allowance	$	(440,920	)	$	(710,639	)
Valuation allowance	(609		)	(3,437		)
Net deferred tax liability	$	(441,529	)	$	(714,076	)

The net deferred tax liability shown above is net of $1.0 million of long-term deferred tax assets as of March 31, 2018 and $1.0 million of long-term deferred tax assets as of March 31, 2017.

At March 31, 2018 and 2017, we have a valuation allowance of $0.6 million and $3.4 million, respectively, related to certain deferred tax assets acquired from Fleet that we have concluded are not more likely than not to be realized. The decrease in the valuation allowance related to the reclassification of $2.8 million into our uncertain tax liability.

A reconciliation of the effective tax rate compared to the statutory U.S. Federal tax rate is as follows:



	Year Ended March 31,
	2018					2017					2016
(In thousands)				%					%					%
Income tax provision at statutory rate	$	37,480		35.0		$	38,798		35.0		$	55,015		35.0
Foreign tax benefit	(2,084		)	(1.9	)	(2,322		)	(2.1	)	(2,894		)	(1.8	)
State income taxes, net of federal income tax benefit	1,414			1.3		1,820			1.7		3,284			2.0
Impact of tax legislation	(268,244		)	(250.5	)	—			—		—			—
Goodwill adjustment for sale of asset	—			—		3,208			2.9		—			—
Nondeductible transaction costs	—			—		686			0.6		1,071			0.7
Nondeductible compensation	—			—		342			0.3		758			0.5
Other	(1,050		)	(1.0	)	(1,077		)	(1.0	)	44			—
Total (benefit) provision for income taxes	$	(232,484	)	(217.1	)	$	41,455		37.4		$	57,278		36.4

Uncertain tax liability activity is as follows:



	2018			2017			2016
(In thousands)
Balance – beginning of year	$	3,651		$	4,084		$	3,420
Additions based on tax positions related to the current year	7,286			583			664
Reductions based on lapse of statute of limitations	(110		)	(1,016		)	—
Balance – end of year	$	10,827		$	3,651		$	4,084

We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. We did not incur any material interest or penalties related to income taxes in 2016, 2017 or 2018. The amount of unrecognized tax benefits at March 31, 2018, 2017, and 2016 was $10.8 million, $3.7 million, and $4.1 million, respectively, which would reduce the effective tax rate by 10.1%, 3.3%, and 2.6%, respectively, if recognized. We do not anticipate any events or circumstances that would cause a significant change to these uncertainties during the ensuing year. We are subject to taxation in the United States and various state and foreign jurisdictions, and we are generally open to examination from the year ended March 31, 2015 forward.

Pursuant to The Tax Act, we recognized a tax liability on any unrepatriated foreign earnings generated through December 31, 2017. Any future foreign earnings may be eligible for the dividends received deduction. As a result, the Company no longer maintains an assertion that any of its foreign earnings are indefinitely reinvested. Consequently, the Company has recorded the U.S. and local country tax effects of repatriating any unremitted foreign earnings.

Commitments and Contingencies

12 Months Ended

Mar. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

We are involved from time to time in routine legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess probability and amount of potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition, or results of operations.

Lease Commitments

We have operating leases for office facilities and equipment, including New York and other locations, which expire at various dates through fiscal 2028. These amounts have been included in the table below.

The following summarizes future minimum lease payments for our operating leases ^(a):



(In thousands)	Facilities		Equipment		Total
Year Ending March 31,
2019	$	2,928	$	333	$	3,261
2020	2,685		138		2,823
2021	2,505		31		2,536
2022	2,163		24		2,187
2023	1,683		10		1,693
Thereafter	8,487		—		8,487
	$	20,451	$	536	$	20,987

(a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.0 million due in the future under non- cancellable subleases.

The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals:



	Year ending March 31,
(In thousands)	2018			2017
Minimum lease payments	$	20,987		$	10,982
Less: Sublease rentals	(1,018		)	(690		)
	$	19,969		$	10,292

Rent expense was $1.9 million, $2.0 million, and $1.8 million for 2018, 2017, and 2016, respectively.

Purchase Commitments

We have supply agreements for the manufacture of some of our products. The following table shows the minimum amounts that we are committed to pay under these agreements:



(In thousands)
Year Ending March 31,	Amount
2019	$	9,473
2020	9,839
2021	9,280
2022	9,280
2023	1,578
Thereafter	—
	$	39,450

Concentrations of Risk	12 Months Ended
Concentrations of Risk	Mar. 31, 2018
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products. We sell our products to mass merchandisers and drug, food, dollar, convenience, and club stores. During 2018, 2017, and 2016, approximately 41.2%, 40.0%, and 41.9%, respectively, of our gross revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. During 2018, 2017, and 2016, Walmart accounted for approximately 23.8%, 21.1%, and 20.2%, respectively, of our gross revenues. At March 31, 2018, approximately 26.1% of our accounts receivable were owed by Walmart. We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri. A serious disruption, such as an earthquake, tornado, flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center. As a result, any such disruption could have a material adverse effect on our business, sales and profitability. At March 31, 2018, we had relationships with 116 third-party manufacturers. Of those, we had long-term contracts with 46 manufacturers that produced items that accounted for approximately 73.6% of our gross sales for 2018, compared to 47 manufacturers with long-term contracts that accounted for approximately 78.4% of gross sales in 2017. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results from operations. Although we are in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

12 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Business Segments

Segment information has been prepared in accordance with the Segment Reporting topic of FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare, (ii) International OTC Healthcare and (iii) Household Cleaning. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses.

The tables below summarize information about our operating and reportable segments.



	Year Ended March 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	868,874	$	91,658	$	80,647	$	1,041,179
Cost of sales	357,298		40,244		67,132		464,674
Gross profit	511,576		51,414		13,515		576,505
Advertising and promotion	129,058		16,267		1,961		147,286
Contribution margin	$	382,518	$	35,147	$	11,554	429,219
Other operating expenses**							213,353
Operating income							215,866
Other expense							108,780
Income before income taxes							107,086
Benefit for income taxes							(232,484		)
Net income							$	339,570

*Intersegment revenues of $7.7 million were eliminated from the North American OTC Healthcare segment.

**Other operating expenses for the year ended March 31, 2018 includes a tradename impairment charge of $99.9 million.



	Year Ended March 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	720,824	$	73,304	$	87,932	$	882,060
Cost of sales	282,750		30,789		68,235		381,774
Gross profit	438,074		42,515		19,697		500,286
Advertising and promotion	112,465		13,434		2,460		128,359
Contribution margin	$	325,609	$	29,081	$	17,237	371,927
Other operating expenses**							166,314
Operating income							205,613
Other expense							94,763
Income before income taxes							110,850
Provision for income taxes							41,455
Net income							$	69,395

* Intersegment revenues of $4.2 million were eliminated from the North American OTC Healthcare segment.

**Other operating expenses for the year ended March 31, 2017 includes a pre-tax net loss of $51.8 million related to divestitures. These divestitures include Pediacare®, New Skin®, Fiber Choice®, e.p.t®, Dermoplast®, and license rights in certain geographic areas pertaining to Comet. The assets and corresponding contribution margin associated with the pre-tax net loss on divestitures related to Pediacare®, New Skin®, Fiber Choice®, e.p.t® and Dermoplast® are included within the North American OTC Healthcare segment, while the pre-tax gain on sale of license rights related to Comet are included in the Household Cleaning segment.



	Year Ended March 31, 2016
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	657,871	$	57,713	$	90,663	$	806,247
Cost of sales	250,018		21,676		67,342		339,036
Gross profit	407,853		36,037		23,321		467,211
Advertising and promotion	97,393		11,114		2,295		110,802
Contribution margin	$	310,460	$	24,923	$	21,026	356,409
Other operating expenses							96,094
Operating income							260,315
Other expense							103,130
Income before income taxes							157,185
Provision for income taxes							57,278
Net income							$	99,907

*Intersegment revenues of $2.7 million were eliminated from the North America OTC Healthcare segment.

The tables below summarize information about our segment revenues from similar product groups.



	Year Ended March 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	118,610	$	807	$	—	$	119,417
Cough & Cold	93,537		18,310		—		111,847
Women's Health	247,244		12,140		—		259,384
Gastrointestinal	117,627		34,609		—		152,236
Eye & Ear Care	92,308		11,744		—		104,052
Dermatologicals	94,775		2,113		—		96,888
Oral Care	99,072		11,930		—		111,002
Other OTC	5,701		5		—		5,706
Household Cleaning	—		—		80,647		80,647
Total segment revenues	$	868,874	$	91,658	$	80,647	$	1,041,179



	Year Ended March 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	120,253	$	1,922	$	—	$	122,175
Cough & Cold	90,795		17,990		—		108,785
Women's Health	147,071		3,811		—		150,882
Gastrointestinal	76,500		24,812		—		101,312
Eye & Ear Care	97,618		12,075		—		109,693
Dermatologicals	85,194		2,159		—		87,353
Oral Care	97,586		10,513		—		108,099
Other OTC	5,807		22		—		5,829
Household Cleaning	—		—		87,932		87,932
Total segment revenues	$	720,824	$	73,304	$	87,932	$	882,060



	Year Ended March 31, 2016
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	117,337	$	2,128	$	—	$	119,465
Cough & Cold	100,148		16,422		—		116,570
Women's Health	132,184		2,982		—		135,166
Gastrointestinal	74,568		20,019		—		94,587
Eye & Ear Care	95,515		11,983		—		107,498
Dermatologicals	82,941		2,133		—		85,074
Oral Care	49,099		2,026		—		51,125
Other OTC	6,079		20		—		6,099
Household Cleaning	—		—		90,663		90,663
Total segment revenues	$	657,871	$	57,713	$	90,663	$	806,247

Our total segment revenues by geographic area are as follows:



	Year Ended March 31,
	2018		2017		2016
United States	$	903,511	$	769,732	$	704,360
Rest of world	137,668		112,328		101,887
Total	$	1,041,179	$	882,060	$	806,247

Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:



March 31, 2018 (In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	580,934	$	32,919	$	6,245	$	620,098

Intangible assets
Indefinite-lived	2,375,736		84,006		30,561		2,490,303
Finite-lived	265,356		6,068		19,189		290,613
Intangible assets, net	2,641,092		90,074		49,750		2,780,916
Total	$	3,222,026	$	122,993	$	55,995	$	3,401,014



March 31, 2017 (In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	576,453	$	32,554	$	6,245	$	615,252

Intangible assets
Indefinite-lived	2,404,336		83,558		101,261		2,589,155
Finite-lived	287,056		6,468		20,934		314,458
Intangible assets, net	2,691,392		90,026		122,195		2,903,613
Total	$	3,267,845	$	122,580	$	128,440	$	3,518,865

Our goodwill and intangible assets by geographic area are as follows:



	Year Ended March 31,
	2018		2017
United States	$	3,278,021	$	3,396,285
Rest of world	122,993		122,580
Total	$	3,401,014	$	3,518,865

Unaudited Quarterly Financial Information

12 Months Ended

Mar. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Unaudited Quarterly Financial Information

Unaudited quarterly financial information for 2018 and 2017 is as follows:

Year Ended March 31, 2018



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2017		September 30, 2017		December 31, 2017			March 31, 2018
Total revenues	$	256,573	$	258,026	$	270,615		$	255,965
Cost of sales	113,097		113,928		122,941			114,708
Gross profit	143,476		144,098		147,674			141,257

Operating expenses
Advertising and promotion	36,944		39,188		35,835			35,319
General and administrative	20,336		21,567		21,207			21,891
Depreciation and amortization	7,167		7,186		7,129			6,946
Tradename impairment	—		—		—			99,924
Total operating expenses	64,447		67,941		64,171			164,080
Operating income	79,029		76,157		83,503			(22,823		)
Net interest expense	26,341		26,836		25,864			26,838
Loss on extinguishment of debt	—		—		—			2,901
Income (loss) before income taxes	52,688		49,321		57,639			(52,562		)
Provision (benefit) for income taxes	18,929		18,616		(257,154		)	(12,875		)
Net income (loss)	$	33,759	$	30,705	$	314,793		$	(39,687	)

Earnings (loss) per share:
Basic	$	0.64	$	0.58	$	5.93		$	(0.75	)
Diluted	$	0.63	$	0.57	$	5.88		$	(0.75	)

Weighted average shares outstanding:
Basic	53,038		53,098		53,129			53,131
Diluted	53,509		53,539		53,543			53,131

Comprehensive income (loss), net of tax:
Currency translation adjustments	1,119		2,716		4,492			(2,625		)
Unrecognized net gain on pension plans	1		—		—			1,334
Total other comprehensive income (loss)	1,120		2,716		4,492			(1,291		)
Comprehensive income (loss)	$	34,879	$	33,421	$	319,285		$	(40,978	)

Year Ended March 31, 2017



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2016			September 30, 2016			December 31, 2016			March 31, 2017
Total revenues	$	209,575		$	215,052		$	216,763		$	240,670
Cost of sales	87,984			91,087			92,216			110,487
Gross profit	121,591			123,965			124,547			130,183

Operating expenses
Advertising and promotion	27,635			28,592			30,682			41,450
General and administrative	19,457			18,795			22,131			28,760
Depreciation and amortization	6,832			6,016			5,852			6,651
Loss (gain) on divestitures	55,453			(496		)	(3,405		)	268
Total operating expenses	109,377			52,907			55,260			77,129
Operating income	12,214			71,058			69,287			53,054
Net interest expense	21,127			20,830			18,554			32,832
Loss on extinguishment of debt	—			—			—			1,420
(Loss) income before income taxes	(8,913		)	50,228			50,733			18,802
(Benefit) provision for income taxes	(3,382		)	18,033			19,092			7,712
Net (loss) income	$	(5,531	)	$	32,195		$	31,641		$	11,090

(Loss) earnings per share:
Basic	$	(0.10	)	$	0.61		$	0.60		$	0.21
Diluted	$	(0.10	)	$	0.60		$	0.59		$	0.21

Weighted average shares outstanding:
Basic	52,881			52,993			52,999			53,009
Diluted	52,881			53,345			53,359			53,419

Comprehensive (loss) income, net of tax:
Currency translation adjustments	(5,824		)	2,703			(8,736		)	9,282
Unrecognized net loss on pension plans	—			—			—			(252		)
Total other comprehensive (loss) income	(5,824		)	2,703			(8,736		)	9,030
Comprehensive (loss) income	$	(11,355	)	$	34,898		$	22,905		$	20,120

Subsequent Events	12 Months Ended
Subsequent Events	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Share Repurchase Program The Company’s Board of Directors authorized the repurchase of up to $50.0 million of the Company’s issued and outstanding common stock. Under the authorization, the Company may purchase common stock through May, 2019 utilizing one or more open market transactions, transactions structured through investment banking institutions, in privately-negotiated transactions or otherwise, by direct purchases of common stock or a combination of the foregoing in compliance with the applicable rules and regulations of the Securities and Exchange Commission. The timing of the purchases and the amount of stock repurchased is subject to the Company's discretion and will depend on market and business conditions, applicable legal and credit requirements and other corporate considerations including the Company’s historical strategy of pursuing accretive acquisitions and deleveraging. Share Based Compensation On May 7, 2018, the Compensation and Talent Management Committee of our Board of Directors granted 103,406 performance units, 100,399 RSUs and stock options to acquire 294,484 shares of our common stock to certain executive officers and employees under the Plan. Performance units are earned based on achievement of the performance objectives set by the Compensation and Talent Management Committee and, if earned, vest in their entirety on the three-year anniversary of the date of grant. RSUs vest either 33.3% per year over three years or in their entirety on the three-year anniversary of the date of grant. Upon vesting, both performance units and RSUs will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $29.46 per share, which is equal to the closing price for our common stock on the date of the grant. Except in cases of death, disability or retirement, termination of employment prior to vesting will result in forfeiture of the unvested performance units, RSUs and the stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan.

Schedule II Valuation and Qualifying Accounts

12 Months Ended

Mar. 31, 2018

Valuation and Qualifying Accounts [Abstract]

Schedule II Valuation and Qualifying Accounts

VALUATION AND QUALIFYING ACCOUNTS



(In thousands)	Balance at Beginning of Year		Amounts Charged to Expense			Deductions			Other				Balance at End of Year
Year Ended March 31, 2018
Reserves for sales returns and allowance	$	9,429	$	62,953		$	(63,569	)	$	—			$	8,813
Reserves for trade promotions	15,193		78,669			(82,427		)	—				11,435
Reserves for consumer coupon redemptions	4,614		7,283			(9,252		)	—				2,645
Allowance for doubtful accounts	1,352		187			(336		)	—				1,203
Deferred tax valuation allowance	3,437		—			—			(2,828		)	^(a)	609

Year Ended March 31, 2017
Reserves for sales returns and allowance	8,823		41,173			(41,417		)	850			^(b)	9,429
Reserves for trade promotions	12,641		69,475			(69,713		)	2,790			^(b)	15,193
Reserves for consumer coupon redemptions	4,323		7,616			(7,745		)	420			^(b)	4,614
Allowance for doubtful accounts	815		177			360			—				1,352
Deferred tax valuation allowance	—		—			—			3,437			^(b)	3,437

Year Ended March 31, 2016
Reserves for sales returns and allowance	6,716		41,217			(40,085		)	975			^(c)	8,823
Reserves for trade promotions	9,932		62,331			(62,409		)	2,787			^(c)	12,641
Reserves for consumer coupon redemptions	1,672		6,235			(5,637		)	2,053			^(c)	4,323
Allowance for doubtful accounts	1,277		(276		)	(186		)	—				815

(a) Reclassified into a FIN 48 liability.

(b) Reflects the applicable amounts acquired from the purchase of Fleet on January 26, 2017.

Business and Basis of Presentation (Policies)

12 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Use of Estimates

Reclassification

Cash and Cash Equivalents

Accounts Receivable

Inventories

Property, Plant and Equipment

Property, plant and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Building	15 - 40
Machinery	3 - 15
Computer equipment and software	3 - 5
Furniture and fixtures	7 - 10
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Goodwill

Intangible Assets

Deferred Origination Costs

Debt Origination Costs

Revenue Recognition

Cost of Sales

Advertising and Promotion Costs

Stock-based Compensation

Pension Expense

Income Taxes

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Recently Issued Accounting Standards

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

Business and Basis of Presentation (Tables)

12 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Property, Plant and Equipment

Property, plant and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Building	15 - 40
Machinery	3 - 15
Computer equipment and software	3 - 5
Furniture and fixtures	7 - 10
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Property, plant and equipment, net consist of the following:



	March 31,
(In thousands)	2018			2017
Components of Property, Plant and Equipment
Land	$	550		$	550
Building	13,746			13,156
Machinery	38,599			31,456
Computer equipment	18,116			15,440
Furniture and fixtures	2,924			2,720
Leasehold improvements	8,804			7,497
	82,739			70,819
Accumulated depreciation	(30,187		)	(20,224		)
Property, plant and equipment, net	$	52,552		$	50,595

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share:



	Year Ended March 31,
(In thousands, except per share data)	2018		2017		2016
Numerator
Net income	$	339,570	$	69,395	$	99,907

Denominator
Denominator for basic earnings per share - weighted average shares outstanding	53,099		52,976		52,754
Dilutive effect of unvested restricted stock units and options issued to employees and directors	427		386		389
Denominator for diluted earnings per share	53,526		53,362		53,143

Earnings per Common Share:
Basic net earnings per share	$	6.40	$	1.31	$	1.89

Diluted net earnings per share	$	6.34	$	1.30	$	1.88

Acquisitions (Tables)

12 Months Ended

Mar. 31, 2018

Business Combinations [Abstract]

Purchase Price Allocation

The following table summarizes our allocation of the assets acquired and liabilities assumed as of the January 26, 2017 acquisition date:



(In thousands)	January 26, 2017

Cash	$	19,884
Accounts receivable	25,293
Inventories	20,812
Prepaid expenses and other current assets	17,024
Property, plant and equipment, net	38,661
Goodwill	273,058
Intangible assets, net	747,600
Other long-term assets	1,137
Total assets acquired	1,143,469

Accounts payable	10,412
Accrued expenses	22,895
Deferred income taxes - long term	261,555
Other long term liabilities	24,884
Total liabilities assumed	319,746
Total purchase price	$	823,723

Pro Forma Information



	Year Ended March 31,
	2017		2016
(In thousands, except per share data)	(Unaudited)
Revenues	$	1,049,473	$	1,004,698
Net income	$	73,750	$	92,712

Earnings per share:
Basic EPS	$	1.39	$	1.76

Diluted EPS	$	1.38	$	1.74

Inventories (Tables)

12 Months Ended

Mar. 31, 2018

Inventory Disclosure [Abstract]

Inventories

Inventories consist of the following:



	March 31,
(In thousands)	2018		2017
Components of Inventories
Packaging and raw materials	$	13,112	$	9,984
Work in process	157		369
Finished goods	105,278		105,256
Inventories	$	118,547	$	115,609

Property, Plant and Equipment (Tables)

12 Months Ended

Mar. 31, 2018

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Building	15 - 40
Machinery	3 - 15
Computer equipment and software	3 - 5
Furniture and fixtures	7 - 10
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Property, plant and equipment, net consist of the following:



	March 31,
(In thousands)	2018			2017
Components of Property, Plant and Equipment
Land	$	550		$	550
Building	13,746			13,156
Machinery	38,599			31,456
Computer equipment	18,116			15,440
Furniture and fixtures	2,924			2,720
Leasehold improvements	8,804			7,497
	82,739			70,819
Accumulated depreciation	(30,187		)	(20,224		)
Property, plant and equipment, net	$	52,552		$	50,595

Goodwill (Tables)

12 Months Ended

Mar. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Changes in Goodwill

The following table summarizes the changes in the carrying value of goodwill by operating segment for each of 2016, 2017, and 2018:



(In thousands)	North American OTC Healthcare			International OTC Healthcare			Household Cleaning			Consolidated
Balance – March 31, 2016	$	330,615		$	22,776		$	6,800		$	360,191

2017 additions	258,438			10,139			—			268,577
2017 reductions	(12,600		)	—			(555		)	(13,155		)
Effects of foreign currency exchange rates	—			(361		)	—			(361		)

Balance – March 31, 2017	576,453			32,554			6,245			615,252

2018 adjustments ^(a)	4,481			—			—			4,481
Effects of foreign currency exchange rates	—			365			—			365

Balance – March 31, 2018	$	580,934		$	32,919		$	6,245		$	620,098

(a) Amount relates to a measurement period adjustment recorded during 2018, associated with our Fleet acquisition.

Intangible Assets (Tables)

12 Months Ended

Mar. 31, 2018

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Reconciliation of the Activity Affecting Intangible Assets

A reconciliation of the activity affecting intangible assets, net for each of 2018 and 2017 is as follows:



	Year Ended March 31, 2018
(In thousands)	Indefinite Lived Tradenames			Finite Lived Tradenames and Customer Relationships			Totals
Gross Amount
Balance – March 31, 2017	$	2,589,155		$	441,801		$	3,030,956
Tradename impairment	(99,300		)	(624		)	(99,924		)
Effects of foreign currency exchange rates	448			137			585
Balance – March 31, 2018	$	2,490,303		$	441,314		$	2,931,617

Accumulated Amortization
Balance – March 31, 2017	$	—		$	127,343		$	127,343
Additions	—			23,349			23,349
Effects of foreign currency exchange rates	—			9			9
Balance – March 31, 2018	$	—		$	150,701		$	150,701

Intangible assets, net – March 31, 2018	$	2,490,303		$	290,613		$	2,780,916

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,375,736		$	265,356		$	2,641,092
International OTC Healthcare	84,006			6,068			90,074
Household Cleaning	30,561			19,189			49,750
Intangible assets, net – March 31, 2018	$	2,490,303		$	290,613		$	2,780,916



	Year Ended March 31, 2017
(In thousands)	Indefinite Lived Tradenames			Finite Lived Tradenames and Customer Relationships			Totals
Gross Amount
Balance – March 31, 2016	$	2,020,046		$	417,880		$	2,437,926
Additions	648,700			98,900			747,600
Reclassifications	(2,064		)	2,064			—
Reductions	(77,248		)	(76,903		)	(154,151		)
Effects of foreign currency exchange rates	(279		)	(140		)	(419		)
Balance – March 31, 2017	$	2,589,155		$	441,801		$	3,030,956

Accumulated Amortization
Balance – March 31, 2016	$	—		$	115,203		$	115,203
Additions	—			19,753			19,753
Reductions	—			(7,610		)	(7,610		)
Effects of foreign currency exchange rates	—			(3		)	(3		)
Balance – March 31, 2017	$	—		$	127,343		$	127,343

Intangible assets, net – March 31, 2017	$	2,589,155		$	314,458		$	2,903,613

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,404,336		$	287,056		$	2,691,392
International OTC Healthcare	83,558			6,468			90,026
Household Cleaning	101,261			20,934			122,195
Intangible assets, net – March 31, 2017	$	2,589,155		$	314,458		$	2,903,613

Schedule of Expected Amortization Expense

At March 31, 2018, finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 30 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):



(In thousands)
Year Ending March 31,	Amount
2019	23,234
2020	23,234
2021	22,812
2022	22,389
2023	22,389
Thereafter	176,555
	$	290,613

Long-Term Debt (Tables)

12 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Schedule of Long-term Debt

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	March 31, 2018			March 31, 2017
2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024.	$	600,000		$	350,000
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	400,000			400,000
2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.00%, or an alternate base rate plus a margin of 1.00% with a floor of 1.00% due on January 26, 2024.	938,000			1,382,000
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 26, 2022.	75,000			90,000
Total long-term debt (including current portion)	2,013,000			2,222,000
Current portion of long-term debt	—			—
Long-term debt	2,013,000			2,222,000
Less: unamortized debt costs	(20,048		)	(28,268		)
Long-term debt, net	$	1,992,952		$	2,193,732

Schedule of Future Principal Payments



(In thousands)
Year Ending March 31,	Amount
2019	$	—
2020	—
2021	—
2022	477,000
2023	9,750
Thereafter	1,526,250
	$	2,013,000

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

Share-Based Compensation (Tables)

12 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Restricted Shares

A summary of the Company’s RSUs granted under the Plan is presented below:



RSUs	Shares (in thousands)		Weighted-Average Grant-Date Fair Value
Vested and nonvested at March 31, 2015	362.3		$	22.74

Granted	266.1		42.41
Vested and issued	(155.6	)	18.31
Forfeited	(5.0	)	39.61
Vested and nonvested at March 31, 2016	467.8		35.22
Vested at March 31, 2016	69.8		14.76

Granted	68.4		55.44
Vested and issued	(94.7	)	28.51
Forfeited	(91.4	)	41.71
Vested and nonvested at March 31, 2017	350.1		39.29
Vested at March 31, 2017	63.4		20.12

Granted	105.8		55.61
Vested and issued	(53.3	)	34.30
Forfeited	(9.1	)	48.76
Vested and nonvested at March 31, 2018	393.5		44.13
Vested at March 31, 2018	90.5		29.88

Stock Options, Valuation Assumptions

The weighted-average grant-date fair values of the options granted during 2018, 2017, and 2016 were $21.20, $21.75, and $17.24, respectively.



	Year Ended March 31,
	2018		2017		2016
Expected volatility	35.2	%	37.8	%	40.2	%
Expected dividends	—		—		—
Expected term in years	6.0		6.0		6.0
Risk-free rate	2.2	%	1.7	%	1.7	%

Stock Option Activity

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted-Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)

Outstanding at March 31, 2015	871.2		$	23.40

Granted	208.2		42.13
Exercised	(348.0	)	19.22
Forfeited or expired	(3.7	)	35.72
Outstanding at March 31, 2016	727.7		30.70

Granted	264.3		55.86
Exercised	(126.8	)	31.75
Forfeited or expired	(92.9	)	42.66
Outstanding at March 31, 2017	772.3		37.70

Granted	182.8		56.11
Exercised	(55.7	)	29.08
Forfeited or expired	(26.2	)	48.19
Outstanding at March 31, 2018	873.2		41.79		7.0	$	2,985
Exercisable at March 31, 2018	495.0		32.41		5.8	$	2,985

Employee Retirement Plans (Tables)

12 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Benefit Obligation and Plan Assets



	Period Ended
(In thousands)	March 31, 2018			March 31, 2017
Change in benefit obligation:
Projected benefit obligation at beginning of period	$	61,714		$	61,187
Interest cost	2,529			456
Actuarial loss	800			791
Benefits paid	(3,161		)	(720		)
Projected benefit obligations at end of year	$	61,882		$	61,714

Change in plan assets:
Fair value of plan assets at beginning of period	$	47,772		$	41,560
Actual return on plan assets	5,505			854
Employer contribution	392			6,078
Benefits paid	(3,161		)	(720		)
Fair value of plan assets at end of year	$	50,508		$	47,772

Funded status at end of year	$	(11,374	)	$	(13,942	)

Schedule of Amounts Recognized in Balance Sheet

Amounts recognized in the balance sheet at the end of the period consist of the following:



	Period Ended
(In thousands)	March 31, 2018		March 31, 2017
Current liability	$	461	463
Long-term liability	10,913		13,479
Total	$	11,374	$	13,942

Schedule of Primary Components of Net Periodic Benefits

The primary components of Net Periodic Benefits consist of the following:



	Period Ended
(In thousands)	March 31, 2018			March 31, 2017
Interest cost	$	2,529		$	456
Expected return on assets	(2,901		)	(462		)
Net periodic benefit cost (income)	$	(372	)	$	(6	)

Schedule of Expected to be Contributed



(In thousands)	Pension Benefits
Employer contributions:
2019 (expectation) to participant benefits	$	1,461

Expected benefit payments year ending March 31,
2019	$	3,314
2020	3,386
2021	3,463
2022	3,588
2023	3,674
2024-2028	19,157

Schedule of Allocation of Plan Assets

The asset allocation for the Company's funded retirement plan as of March 31, 2018 and 2017, and the target allocation by asset category are as follows:



	Percentage of Plan Assets
Asset Category	Target Allocation		March 31, 2018		March 31, 2017
Domestic large cap equities	21	%	21	%	41	%
Domestic small/mid cap equities	6		6		7
International equities	18		18		16
Balanced/asset allocation	—		—		2
Fixed income and cash	55		55		34
Total	100	%	100	%	100	%

Schedule of Amounts in Accumulated Other Comprehensive Income (Loss)



(In thousands)
Balances in accumulated other comprehensive loss as of March 31, 2017:
Unrecognized actuarial loss	$	399
Unrecognized prior service credit	—

Balances in accumulated other comprehensive (income) as of March 31, 2018:
Unrecognized actuarial (gain)	$	(1,407	)
Unrecognized prior service credit	—

Amounts expected to be reclassified from accumulated other comprehensive income (loss) during 2019:
Unrecognized actuarial (loss)	$	—
Unrecognized prior service credit	—

Schedule of Assumptions Used

Assumptions used in determining the actuarial present value of the benefit obligation as of March 31, 2018 and 2017 were as follows:



	Period Ended
	March 31, 2018	March 31, 2017
Key assumptions:
Discount rate	3.93% to 4.07%	3.92% to 4.21%
Expected return on plan assets, net of administrative fees	6.25%	6.25%
Rate of compensation increase	—	—

Income Taxes (Tables)

12 Months Ended

Mar. 31, 2018

Income Tax Disclosure [Abstract]

Income from Continuing Operations Before Income Taxes, Domestic and Foreign

Income before income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2018		2017		2016
United States	$	84,435	$	93,582	$	142,253
Foreign	22,651		17,268		14,932
	$	107,086	$	110,850	$	157,185

Components of Provision for Income Taxes

The provision for income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2018			2017			2016
Current
Federal	$	31,327		$	40,183		$	6,080
State	2,686			2,808			1,171
Foreign	5,588			4,242			3,905
Deferred
Federal	(270,796		)	(5,421		)	44,787
State	(1,240		)	(163		)	1,678
Foreign	(49		)	(194		)	(343		)
Total (benefit) provision for income taxes	$	(232,484	)	$	41,455		$	57,278

Components of Deferred Tax Balances

The principal components of our deferred tax balances are as follows:



	March 31,
(In thousands)	2018			2017
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$	2,806		$	5,280
Inventory capitalization	1,176			1,881
Inventory reserves	540			1,880
Net operating loss carryforwards	609			609
State income taxes	10,154			17,727
Accrued liabilities	2,210			2,174
Accrued compensation	4,992			9,574
Stock compensation	5,038			5,790
Other	4,975			7,925
Total deferred tax assets	$	32,500		$	52,840

Deferred Tax Liabilities
Property, plant and equipment	$	(6,032	)	$	(9,157	)
Intangible assets	(467,388		)	(754,322		)
Total deferred tax liabilities	$	(473,420	)	$	(763,479	)

Net deferred tax liability before valuation allowance	$	(440,920	)	$	(710,639	)
Valuation allowance	(609		)	(3,437		)
Net deferred tax liability	$	(441,529	)	$	(714,076	)

Reconciliation of Effective Tax Rate

A reconciliation of the effective tax rate compared to the statutory U.S. Federal tax rate is as follows:



	Year Ended March 31,
	2018					2017					2016
(In thousands)				%					%					%
Income tax provision at statutory rate	$	37,480		35.0		$	38,798		35.0		$	55,015		35.0
Foreign tax benefit	(2,084		)	(1.9	)	(2,322		)	(2.1	)	(2,894		)	(1.8	)
State income taxes, net of federal income tax benefit	1,414			1.3		1,820			1.7		3,284			2.0
Impact of tax legislation	(268,244		)	(250.5	)	—			—		—			—
Goodwill adjustment for sale of asset	—			—		3,208			2.9		—			—
Nondeductible transaction costs	—			—		686			0.6		1,071			0.7
Nondeductible compensation	—			—		342			0.3		758			0.5
Other	(1,050		)	(1.0	)	(1,077		)	(1.0	)	44			—
Total (benefit) provision for income taxes	$	(232,484	)	(217.1	)	$	41,455		37.4		$	57,278		36.4

Uncertain Tax Liability Activity

Uncertain tax liability activity is as follows:



	2018			2017			2016
(In thousands)
Balance – beginning of year	$	3,651		$	4,084		$	3,420
Additions based on tax positions related to the current year	7,286			583			664
Reductions based on lapse of statute of limitations	(110		)	(1,016		)	—
Balance – end of year	$	10,827		$	3,651		$	4,084

Commitments and Contingencies (Tables)

12 Months Ended

Mar. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

The following summarizes future minimum lease payments for our operating leases ^(a):



(In thousands)	Facilities		Equipment		Total
Year Ending March 31,
2019	$	2,928	$	333	$	3,261
2020	2,685		138		2,823
2021	2,505		31		2,536
2022	2,163		24		2,187
2023	1,683		10		1,693
Thereafter	8,487		—		8,487
	$	20,451	$	536	$	20,987

(a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.0 million due in the future under non- cancellable subleases.

The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals:



	Year ending March 31,
(In thousands)	2018			2017
Minimum lease payments	$	20,987		$	10,982
Less: Sublease rentals	(1,018		)	(690		)
	$	19,969		$	10,292

Unrecorded Unconditional Purchase Obligations

The following table shows the minimum amounts that we are committed to pay under these agreements:



(In thousands)
Year Ending March 31,	Amount
2019	$	9,473
2020	9,839
2021	9,280
2022	9,280
2023	1,578
Thereafter	—
	$	39,450

Business Segments (Tables)

12 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Information about our Operating and Reportable Segments

The tables below summarize information about our operating and reportable segments.



	Year Ended March 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	868,874	$	91,658	$	80,647	$	1,041,179
Cost of sales	357,298		40,244		67,132		464,674
Gross profit	511,576		51,414		13,515		576,505
Advertising and promotion	129,058		16,267		1,961		147,286
Contribution margin	$	382,518	$	35,147	$	11,554	429,219
Other operating expenses**							213,353
Operating income							215,866
Other expense							108,780
Income before income taxes							107,086
Benefit for income taxes							(232,484		)
Net income							$	339,570

*Intersegment revenues of $7.7 million were eliminated from the North American OTC Healthcare segment.

**Other operating expenses for the year ended March 31, 2018 includes a tradename impairment charge of $99.9 million.



	Year Ended March 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	720,824	$	73,304	$	87,932	$	882,060
Cost of sales	282,750		30,789		68,235		381,774
Gross profit	438,074		42,515		19,697		500,286
Advertising and promotion	112,465		13,434		2,460		128,359
Contribution margin	$	325,609	$	29,081	$	17,237	371,927
Other operating expenses**							166,314
Operating income							205,613
Other expense							94,763
Income before income taxes							110,850
Provision for income taxes							41,455
Net income							$	69,395

* Intersegment revenues of $4.2 million were eliminated from the North American OTC Healthcare segment.



	Year Ended March 31, 2016
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Total segment revenues*	$	657,871	$	57,713	$	90,663	$	806,247
Cost of sales	250,018		21,676		67,342		339,036
Gross profit	407,853		36,037		23,321		467,211
Advertising and promotion	97,393		11,114		2,295		110,802
Contribution margin	$	310,460	$	24,923	$	21,026	356,409
Other operating expenses							96,094
Operating income							260,315
Other expense							103,130
Income before income taxes							157,185
Provision for income taxes							57,278
Net income							$	99,907

*Intersegment revenues of $2.7 million were eliminated from the North America OTC Healthcare segment.

Information about our Revenues from Similar Product Groups

The tables below summarize information about our segment revenues from similar product groups.



	Year Ended March 31, 2018
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	118,610	$	807	$	—	$	119,417
Cough & Cold	93,537		18,310		—		111,847
Women's Health	247,244		12,140		—		259,384
Gastrointestinal	117,627		34,609		—		152,236
Eye & Ear Care	92,308		11,744		—		104,052
Dermatologicals	94,775		2,113		—		96,888
Oral Care	99,072		11,930		—		111,002
Other OTC	5,701		5		—		5,706
Household Cleaning	—		—		80,647		80,647
Total segment revenues	$	868,874	$	91,658	$	80,647	$	1,041,179



	Year Ended March 31, 2017
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	120,253	$	1,922	$	—	$	122,175
Cough & Cold	90,795		17,990		—		108,785
Women's Health	147,071		3,811		—		150,882
Gastrointestinal	76,500		24,812		—		101,312
Eye & Ear Care	97,618		12,075		—		109,693
Dermatologicals	85,194		2,159		—		87,353
Oral Care	97,586		10,513		—		108,099
Other OTC	5,807		22		—		5,829
Household Cleaning	—		—		87,932		87,932
Total segment revenues	$	720,824	$	73,304	$	87,932	$	882,060



	Year Ended March 31, 2016
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	117,337	$	2,128	$	—	$	119,465
Cough & Cold	100,148		16,422		—		116,570
Women's Health	132,184		2,982		—		135,166
Gastrointestinal	74,568		20,019		—		94,587
Eye & Ear Care	95,515		11,983		—		107,498
Dermatologicals	82,941		2,133		—		85,074
Oral Care	49,099		2,026		—		51,125
Other OTC	6,079		20		—		6,099
Household Cleaning	—		—		90,663		90,663
Total segment revenues	$	657,871	$	57,713	$	90,663	$	806,247

Segment Revenue by Geographic Area

Our total segment revenues by geographic area are as follows:



	Year Ended March 31,
	2018		2017		2016
United States	$	903,511	$	769,732	$	704,360
Rest of world	137,668		112,328		101,887
Total	$	1,041,179	$	882,060	$	806,247

Allocation of Long-Term Assets to Segments

Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:



March 31, 2018 (In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	580,934	$	32,919	$	6,245	$	620,098

Intangible assets
Indefinite-lived	2,375,736		84,006		30,561		2,490,303
Finite-lived	265,356		6,068		19,189		290,613
Intangible assets, net	2,641,092		90,074		49,750		2,780,916
Total	$	3,222,026	$	122,993	$	55,995	$	3,401,014



March 31, 2017 (In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	576,453	$	32,554	$	6,245	$	615,252

Intangible assets
Indefinite-lived	2,404,336		83,558		101,261		2,589,155
Finite-lived	287,056		6,468		20,934		314,458
Intangible assets, net	2,691,392		90,026		122,195		2,903,613
Total	$	3,267,845	$	122,580	$	128,440	$	3,518,865

Goodwill and Intangible Assets by Geographic Areas

Our goodwill and intangible assets by geographic area are as follows:



	Year Ended March 31,
	2018		2017
United States	$	3,278,021	$	3,396,285
Rest of world	122,993		122,580
Total	$	3,401,014	$	3,518,865

Unaudited Quarterly Financial Information (Tables)

12 Months Ended

Mar. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information

Unaudited quarterly financial information for 2018 and 2017 is as follows:

Year Ended March 31, 2018



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2017		September 30, 2017		December 31, 2017			March 31, 2018
Total revenues	$	256,573	$	258,026	$	270,615		$	255,965
Cost of sales	113,097		113,928		122,941			114,708
Gross profit	143,476		144,098		147,674			141,257

Operating expenses
Advertising and promotion	36,944		39,188		35,835			35,319
General and administrative	20,336		21,567		21,207			21,891
Depreciation and amortization	7,167		7,186		7,129			6,946
Tradename impairment	—		—		—			99,924
Total operating expenses	64,447		67,941		64,171			164,080
Operating income	79,029		76,157		83,503			(22,823		)
Net interest expense	26,341		26,836		25,864			26,838
Loss on extinguishment of debt	—		—		—			2,901
Income (loss) before income taxes	52,688		49,321		57,639			(52,562		)
Provision (benefit) for income taxes	18,929		18,616		(257,154		)	(12,875		)
Net income (loss)	$	33,759	$	30,705	$	314,793		$	(39,687	)

Earnings (loss) per share:
Basic	$	0.64	$	0.58	$	5.93		$	(0.75	)
Diluted	$	0.63	$	0.57	$	5.88		$	(0.75	)

Weighted average shares outstanding:
Basic	53,038		53,098		53,129			53,131
Diluted	53,509		53,539		53,543			53,131

Comprehensive income (loss), net of tax:
Currency translation adjustments	1,119		2,716		4,492			(2,625		)
Unrecognized net gain on pension plans	1		—		—			1,334
Total other comprehensive income (loss)	1,120		2,716		4,492			(1,291		)
Comprehensive income (loss)	$	34,879	$	33,421	$	319,285		$	(40,978	)

Year Ended March 31, 2017



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2016			September 30, 2016			December 31, 2016			March 31, 2017
Total revenues	$	209,575		$	215,052		$	216,763		$	240,670
Cost of sales	87,984			91,087			92,216			110,487
Gross profit	121,591			123,965			124,547			130,183

Operating expenses
Advertising and promotion	27,635			28,592			30,682			41,450
General and administrative	19,457			18,795			22,131			28,760
Depreciation and amortization	6,832			6,016			5,852			6,651
Loss (gain) on divestitures	55,453			(496		)	(3,405		)	268
Total operating expenses	109,377			52,907			55,260			77,129
Operating income	12,214			71,058			69,287			53,054
Net interest expense	21,127			20,830			18,554			32,832
Loss on extinguishment of debt	—			—			—			1,420
(Loss) income before income taxes	(8,913		)	50,228			50,733			18,802
(Benefit) provision for income taxes	(3,382		)	18,033			19,092			7,712
Net (loss) income	$	(5,531	)	$	32,195		$	31,641		$	11,090

(Loss) earnings per share:
Basic	$	(0.10	)	$	0.61		$	0.60		$	0.21
Diluted	$	(0.10	)	$	0.60		$	0.59		$	0.21

Weighted average shares outstanding:
Basic	52,881			52,993			52,999			53,009
Diluted	52,881			53,345			53,359			53,419

Comprehensive (loss) income, net of tax:
Currency translation adjustments	(5,824		)	2,703			(8,736		)	9,282
Unrecognized net loss on pension plans	—			—			—			(252		)
Total other comprehensive (loss) income	(5,824		)	2,703			(8,736		)	9,030
Comprehensive (loss) income	$	(11,355	)	$	34,898		$	22,905		$	20,120

Business and Basis of Presentation (Cash and Cash Equivalents) (Details) $ in Millions	12 Months Ended
	Mar. 31, 2018 USD ($)
Cash and Cash Equivalents [Line Items]
Non-cash financing activities	$ 0.6
Sydney, Australia
Cash and Cash Equivalents [Line Items]
Percentage of deposits held in one location (as percent)	23.00%

Business and Basis of Presentation (Property, Plant and Equipment) (Details)	12 Months Ended
	Mar. 31, 2018
Building \| Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	15 years
Building \| Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	40 years
Machinery \| Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Machinery \| Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	15 years
Computer Equipment and Software \| Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Computer Equipment and Software \| Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	5 years
Furniture and fixtures \| Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	7 years
Furniture and fixtures \| Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	10 years

Business and Basis of Presentation (Cost of Sales) (Details) - USD ($) $ in Millions	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Warehousing, shipping and handling, and storage costs	$ 64.7	$ 46.2	$ 39.2

Business and Basis of Presentation (Income Taxes) (Details) $ in Millions	12 Months Ended
	Mar. 31, 2018 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net gain related to deferred tax liability	$ 267.0
Net gain related to the lower blended tax rate	3.2
Net gain	270.2
Repatriation charge	$ 1.9

Business and Basis of Presentation (Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Numerator
Net income	$ (39,687)	$ 314,793	$ 30,705	$ 33,759	$ 11,090	$ 31,641	$ 32,195	$ (5,531)	$ 339,570	$ 69,395	$ 99,907
Denominator
Denominator for basic earnings per share - weighted average shares (in shares)	53,131	53,129	53,098	53,038	53,009	52,999	52,993	52,881	53,099	52,976	52,754
Dilutive effect of unvested restricted common stock and options issued to employees and directors (in shares)									427	386	389
Denominator for diluted earnings per share (in shares)	53,131	53,543	53,539	53,509	53,419	53,359	53,345	52,881	53,526	53,362	53,143
Earnings per Common Share:
Basic net earnings per share (in USD per share)	$ (0.75)	$ 5.93	$ 0.58	$ 0.64	$ 0.21	$ 0.60	$ 0.61	$ (0.10)	$ 6.40	$ 1.31	$ 1.89
Diluted net earnings per share (in USD per share)	$ (0.75)	$ 5.88	$ 0.57	$ 0.63	$ 0.21	$ 0.59	$ 0.60	$ (0.10)	$ 6.34	$ 1.30	$ 1.88
Antidilutive securities excluded from computation of earnings per share (in shares)									400	200	100

Acquisitions (Narrative) (Details) - USD ($)			1 Months Ended	12 Months Ended
Acquisitions (Narrative) (Details) - USD ($)	Jan. 26, 2017	Feb. 05, 2016	Dec. 31, 2016	Mar. 31, 2018
Business Acquisition [Line Items]
Goodwill, post-closing inventory and apportionment adjustment				$ (4,481,000)
C.B. Fleet Company, Inc.
Business Acquisition [Line Items]
Purchase price	$ 823,700,000
Indefinite-lived intangible assets	648,700,000
Finite-lived intangible assets	98,900,000
Goodwill, post-closing inventory and apportionment adjustment	273,100,000
C.B. Fleet Company, Inc. \| Term Loans
Business Acquisition [Line Items]
Debt instrument, face amount	$ 740,000,000
DenTek Oral Care, Inc.
Business Acquisition [Line Items]
Purchase price		$ 226,900,000
Goodwill, post-closing inventory and apportionment adjustment			$ (2,800,000)

Acquisitions (Allocations) (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017	Jan. 26, 2017	Mar. 31, 2016
Purchase Price
Goodwill	$ 620,098	$ 615,252		$ 360,191
C.B. Fleet Company, Inc.
Purchase Price
Cash			$ 19,884
Accounts receivable			25,293
Inventories			20,812
Prepaids and other current assets			17,024
Property, plant and equipment, net			38,661
Goodwill			273,058
Intangible assets, net			747,600
Other long-term assets			1,137
Total assets acquired			1,143,469
Accounts payable			10,412
Accrued expenses			22,895
Deferred income taxes - long term			261,555
Other long term liabilities			24,884
Total liabilities assumed			319,746
Net assets acquired			$ 823,723

Acquisitions (Pro Forma) (Details) - C.B. Fleet Company, Inc. - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Pro Forma Information
Revenues	$ 1,049,473	$ 1,004,698
Net income	$ 73,750	$ 92,712
Earnings per share:
Basic (in USD per share)	$ 1.39	$ 1.76
Diluted (in USD per share)	$ 1.38	$ 1.74

Divestitures and Sale of License Rights (Narrative) (Details) - USD ($) $ in Thousands			1 Months Ended				3 Months Ended				12 Months Ended
	Dec. 30, 2016	Jul. 07, 2016	Dec. 31, 2016	Sep. 30, 2016	Aug. 31, 2016	Dec. 31, 2014	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on divestitures							$ 268	$ (3,405)	$ (496)	$ 55,453	$ 0	$ 51,820	$ 0
Comet Brand
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Early Buyout						$ 10,000
Royalty revenue						1,000
Proceeds from sale of license rights					$ 11,000	$ 10,000
Gain on sale of asset					1,200
Indefinite-lived intangibles, reductions					$ 9,000
Disposal group, disposed of by sale, not discontinued operations \| Pediacare, New Skin and Fiber Choice \| Cough and Cold, Dermatologicals, and Gastrointestinal products group \| North American OTC Healthcare
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration, excluding costs of inventory		$ 40,000
Loss on divestitures												$ 56,200
Indefinite-lived intangibles, reductions		$ 37,200
Disposal group, disposed of by sale, not discontinued operations \| Dermoplast \| Cough and Cold, Dermatologicals, and Gastrointestinal products group \| North American OTC Healthcare
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Deposit for agreement to purchase				$ 1,250
Indefinite-lived intangibles, reductions	$ 31,000
Disposal group, disposed of by sale, not discontinued operations \| E.P.T. and Dermoplast \| Cough and Cold, Dermatologicals, and Gastrointestinal products group \| North American OTC Healthcare
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total purchase price received			$ 59,600					$ 59,600
Pre-tax net gain on divestitures			$ 3,900

Accounts Receivable (Schedule of Accounts Receivable) (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 153,615	$ 149,752
Less allowances for discounts, returns and uncollectible accounts	(12,734)	(13,010)
Accounts receivable, net	140,881	136,742
Trade accounts receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	152,832	148,339
Other receivables
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 783	$ 1,413

Inventories (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 13,112	$ 9,984
Work in process	157	369
Finished goods	105,278	105,256
Inventories	118,547	115,609
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 4,200	$ 6,600

Property, Plant and Equipment (Schedule of Property, Plant and Equipment, Net) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Components of Property, Plant and Equipment
Property, plant and equipment, gross	$ 82,739	$ 70,819
Accumulated depreciation	(30,187)	(20,224)
Property, plant and equipment, net	52,552	50,595
Depreciation expense	10,100	6,000	$ 5,200
Land
Components of Property, Plant and Equipment
Property, plant and equipment, gross	550	550
Building
Components of Property, Plant and Equipment
Property, plant and equipment, gross	13,746	13,156
Machinery
Components of Property, Plant and Equipment
Property, plant and equipment, gross	38,599	31,456
Computer equipment
Components of Property, Plant and Equipment
Property, plant and equipment, gross	18,116	15,440
Furniture and fixtures
Components of Property, Plant and Equipment
Property, plant and equipment, gross	2,924	2,720
Leasehold improvements
Components of Property, Plant and Equipment
Property, plant and equipment, gross	$ 8,804	$ 7,497

Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
Goodwill (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Goodwill [Roll Forward]
Goodwill, net, beginning	$ 615,252	$ 360,191
Additions		268,577
Reductions		(13,155)
Adjustments	4,481
Effects of foreign currency exchange rates	365	(361)
Goodwill, net, ending	620,098	615,252
North American OTC Healthcare
Goodwill [Roll Forward]
Goodwill, net, beginning	576,453	330,615
Additions		258,438
Reductions		(12,600)
Adjustments	4,481
Effects of foreign currency exchange rates	0	0
Goodwill, net, ending	580,934	576,453
International OTC Healthcare
Goodwill [Roll Forward]
Goodwill, net, beginning	32,554	22,776
Additions		10,139
Reductions		0
Adjustments	0
Effects of foreign currency exchange rates	365	(361)
Goodwill, net, ending	32,919	32,554
Household Cleaning
Goodwill [Roll Forward]
Goodwill, net, beginning	6,245	6,800
Additions		0
Reductions		(555)
Adjustments	0
Effects of foreign currency exchange rates	0	0
Goodwill, net, ending	$ 6,245	$ 6,245

Goodwill (Narrative) (Details) - USD ($)					1 Months Ended			12 Months Ended
Goodwill (Narrative) (Details) - USD ($)	Jan. 26, 2017	Dec. 30, 2016	Dec. 28, 2016	Jul. 07, 2016	Dec. 31, 2016	Aug. 31, 2016	Dec. 31, 2014	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Feb. 28, 2018	Feb. 05, 2016
Goodwill [Line Items]
Goodwill								$ 620,098,000	$ 615,252,000	$ 360,191,000
Proceeds from acquisition								970,000	0	0
Goodwill, post-closing inventory and apportionment adjustment								(4,481,000)
Goodwill impairment charge								0	0
Reporting unit, fair value in excess of carrying amount (percent)											19.00%
North American OTC Healthcare
Goodwill [Line Items]
Goodwill								580,934,000	$ 576,453,000	$ 330,615,000
Goodwill, post-closing inventory and apportionment adjustment								$ (4,481,000)
Cough and Cold, Dermatologicals, and Gastrointestinal products group \| Disposal group, disposed of by sale, not discontinued operations \| Pediacare, New Skin and Fiber Choice \| North American OTC Healthcare
Goodwill [Line Items]
Goodwill, written off related to sale of business unit				$ 2,900,000
Consideration, excluding costs of inventory				$ 40,000,000
Cough and Cold, Dermatologicals, and Gastrointestinal products group \| Disposal group, disposed of by sale, not discontinued operations \| Dermoplast \| North American OTC Healthcare
Goodwill [Line Items]
Goodwill, written off related to sale of business unit		$ 5,500,000
Cough and Cold, Dermatologicals, and Gastrointestinal products group \| Disposal group, disposed of by sale, not discontinued operations \| E.P.T. \| North American OTC Healthcare
Goodwill [Line Items]
Goodwill, written off related to sale of business unit			$ 1,400,000
DenTek Oral Care, Inc.
Goodwill [Line Items]
Goodwill												$ 73,700,000
Proceeds from acquisition					$ 1,400,000
Goodwill, post-closing inventory and apportionment adjustment					(2,800,000)
Goodwill, purchase accounting adjustments and other post closing adjustments					$ 1,400,000
C.B. Fleet Company, Inc.
Goodwill [Line Items]
Goodwill	$ 273,058,000
Goodwill, post-closing inventory and apportionment adjustment	$ 273,100,000
Comet Brand
Goodwill [Line Items]
Gain on sale of asset							$ 1,300,000
Goodwill, written off related to sale of business unit						$ 600,000

Intangible Assets (Reconciliation of Activity) (Details) - USD ($) $ in Thousands	3 Months Ended				12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning				$ 2,589,155	$ 2,589,155
Indefinite-lived intangibles, ending	$ 2,490,303				2,490,303	$ 2,589,155
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived intangibles, tradename impairment	(99,924)	$ 0	$ 0	0	(99,924)	0	$ 0
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-lived intangibles, accumulated amortization, beginning				127,343	127,343	115,203
Finite-lived intangibles, accumulated amortization, additions					23,300	19,753
Finite-lived intangible assets, accumulated amortization, reductions						(7,610)
Finite-lived intangibles, accumulated amortization, effects of foreign currency exchange rates						(3)
Finite-lived intangibles, accumulated amortization, ending						127,343	115,203
Intangible Assets, Gross [Abstract]
Intangible assets, gross, beginning				3,030,956	3,030,956	2,437,926
Intangible assets, additions						747,600
Intangible assets, tradename impairment					(99,924)
Intangible assets, reclassifications						0
Intangible assets, reductions						(154,151)
Intangible assets, effects of foreign currency exchange rates					585	(419)
Intangible assets, gross, ending	2,931,617				2,931,617	3,030,956	2,437,926
Finite-lived intangible assets	290,613				290,613	314,458
Intangible assets, net (excluding goodwill)	2,780,916				2,780,916	2,903,613
North American OTC Healthcare
Intangible Assets, Gross [Abstract]
Intangible assets, net (excluding goodwill)	2,641,092				2,641,092	2,691,392
International OTC Healthcare
Intangible Assets, Gross [Abstract]
Intangible assets, net (excluding goodwill)	90,074				90,074	90,026
Household Cleaning
Intangible Assets, Gross [Abstract]
Intangible assets, net (excluding goodwill)	49,750				49,750	122,195
Finite Lived Tradenames and Customer Relationships
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived intangibles, gross, beginning				441,801	441,801	417,880
Finite-lived intangibles, additions						98,900
Finite-lived intangibles, tradename impairment					(624)
Finite-lived intangibles, reclassified						2,064
Finite-lived intangibles, reductions						(76,903)
Finite-lived intangibles, effects of foreign currency exchange rates					137	(140)
Finite-lived intangibles, gross, ending	441,314				441,314	441,801	417,880
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-lived intangibles, accumulated amortization, beginning				127,343	127,343	115,203
Finite-lived intangibles, accumulated amortization, additions					23,349	19,753
Finite-lived intangible assets, accumulated amortization, reductions						(7,610)
Finite-lived intangibles, accumulated amortization, effects of foreign currency exchange rates					9	(3)
Finite-lived intangibles, accumulated amortization, ending	150,701				150,701	127,343	115,203
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	290,613				290,613	314,458
Finite Lived Tradenames and Customer Relationships \| North American OTC Healthcare
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	265,356				265,356	287,056
Finite Lived Tradenames and Customer Relationships \| International OTC Healthcare
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	6,068				6,068	6,468
Finite Lived Tradenames and Customer Relationships \| Household Cleaning
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	19,189				19,189	20,934
Indefinite Lived Tradenames
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning				2,589,155	2,589,155	2,020,046
Indefinite-lived intangibles, additions						648,700
Indefinite-lived intangibles, reclassifications						(2,064)
Indefinite-lived intangibles, tradename impairment					(99,300)
Indefinite-lived intangibles, reductions						(77,248)
Indefinite-lived intangibles, effects of foreign currency exchange rates					448	(279)
Indefinite-lived intangibles, ending	2,490,303				2,490,303	2,589,155	$ 2,020,046
Indefinite Lived Tradenames \| North American OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning				2,404,336	2,404,336
Indefinite-lived intangibles, ending	2,375,736				2,375,736	2,404,336
Indefinite Lived Tradenames \| International OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning				83,558	83,558
Indefinite-lived intangibles, ending	84,006				84,006	83,558
Indefinite Lived Tradenames \| Household Cleaning
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning				$ 101,261	101,261
Indefinite-lived intangibles, ending	$ 30,561				$ 30,561	$ 101,261

Intangible Assets (Narrative) (Details) $ in Thousands			1 Months Ended			3 Months Ended								11 Months Ended	12 Months Ended
Intangible Assets (Narrative) (Details) $ in Thousands	Dec. 30, 2016 USD ($)	Jul. 07, 2016 USD ($)	Dec. 31, 2016 USD ($)	Aug. 31, 2016 USD ($)	Dec. 31, 2014 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Feb. 28, 2018 USD ($) trade_name	Mar. 31, 2018 USD ($)	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Jan. 26, 2017 USD ($)	Feb. 05, 2016 USD ($)
Schedule of Intangible Assets [Line Items]
Proceeds from divestitures															$ 0	$ 110,717	$ 0
Loss on divestitures										$ 268	$ (3,405)	$ (496)	$ 55,453		0	51,820	0
Number of indefinite-lived trade names exceeding carrying value by less than 10% \| trade_name														2
Impairment of finite-lived assets						$ 99,924	$ 0	$ 0	$ 0						$ 99,924	0	$ 0
Finite-lived intangible assets, weighted average remaining period															12 years 5 months 24 days
Amortization of intangible assets															$ 23,300	19,753
Minimum
Schedule of Intangible Assets [Line Items]
Intangible assets, useful lives															10 years
Maximum
Schedule of Intangible Assets [Line Items]
Intangible assets, useful lives															30 years
Cost of capital
Schedule of Intangible Assets [Line Items]
Increase (decrease) in fair value measurement input														0.0050
Impact of change in measurement input on indefinite-lived asset impairment														$ 4,200
Massengill brand
Schedule of Intangible Assets [Line Items]
Impairment of finite-lived assets															$ 600
Tradenames
Schedule of Intangible Assets [Line Items]
Indefinite-lived intangibles, reductions				$ 9,000
Tradenames \| Terminal growth rate
Schedule of Intangible Assets [Line Items]
Increase (decrease) in fair value measurement input														(0.0050)
Impact of change in measurement input on indefinite-lived asset impairment														$ 2,300
Beano Brand
Schedule of Intangible Assets [Line Items]
Impairment of indefinite-lived assets															28,600
Tradenames														49,800
Comet Brand
Schedule of Intangible Assets [Line Items]
Indefinite-lived intangibles, reductions				9,000
Proceeds from the sale of property and equipment				11,000	$ 10,000
Agreement election amount per quarter									$ 1,000
Gain on sale of asset				$ 1,200
Impairment of indefinite-lived assets															$ 70,700
Tradenames														$ 30,600
Disposal group, disposed of by sale, not discontinued operations \| Pediacare, New Skin and Fiber Choice \| North American OTC Healthcare \| Cough and Cold, Dermatologicals, and Gastrointestinal products group
Schedule of Intangible Assets [Line Items]
Consideration, excluding costs of inventory		$ 40,000
Proceeds from divestitures		40,100
Indefinite-lived intangibles, reductions		37,200
Finite-lived intangible assets, written off		$ 54,000
Loss on divestitures																$ 56,200
Disposal group, disposed of by sale, not discontinued operations \| Dermoplast \| North American OTC Healthcare \| Cough and Cold, Dermatologicals, and Gastrointestinal products group
Schedule of Intangible Assets [Line Items]
Proceeds from divestitures	$ 48,400
Indefinite-lived intangibles, reductions	$ 31,000
Disposal group, disposed of by sale, not discontinued operations \| E.P.T. \| North American OTC Healthcare \| Cough and Cold, Dermatologicals, and Gastrointestinal products group
Schedule of Intangible Assets [Line Items]
Indefinite-lived intangibles, reductions			$ 14,800
DenTek Oral Care, Inc.
Schedule of Intangible Assets [Line Items]
Intangible assets acquired																			$ 206,700
C.B. Fleet Company, Inc.
Schedule of Intangible Assets [Line Items]
Intangible assets acquired																		$ 747,600

Intangible Assets (Expected Amortization Expense) (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Intangible Assets, Net (Excluding Goodwill) [Abstract]
2019	$ 23,234
2020	23,234
2021	22,812
2022	22,389
2023	22,389
Thereafter	176,555
Intangible assets, net	$ 290,613	$ 314,458

Other Accrued Liabilities (Schedule of Other Accrued Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Payables and Accruals [Abstract]
Accrued marketing costs	$ 21,473	$ 29,384
Accrued compensation costs	10,591	15,535
Accrued broker commissions	1,487	1,782
Income taxes payable	1,901	3,840
Accrued professional fees	2,244	2,412
Accrued production costs	7,392	4,580
Income tax related payable	0	19,000
Other accrued liabilities	7,013	7,128
Total other accrued liabilities	$ 52,101	$ 83,661

Long-Term Debt (Narrative 2012 Term Loan and 2012 ABL Revolver) (Details) - USD ($)							12 Months Ended	38 Months Ended
	Mar. 21, 2018	Feb. 04, 2016	Jun. 09, 2015	Sep. 03, 2014	Feb. 21, 2013	Jan. 31, 2012	Mar. 31, 2018	Mar. 31, 2015	Jan. 26, 2017	May 08, 2015
2012 ABL Revolver \| Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, term						5 years
Line of credit facility, maximum borrowing capacity						$ 50,000,000.0	$ 135,000,000
Revolving credit facility, increase in borrowing capacity							$ 85,000,000
Debt instrument, interest rate, decrease (as percent)								0.25%
Line of credit facility, commitment fee (as percent)						0.50%
Line of credit facility, conditional commitment fee (as percent)							0.375%
Revolver increase in accordion feature			$ 35,000,000.0
Debt instrument, average interest rate (as percent)							2.70%
2012 ABL Revolver \| Revolving Credit Facility \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component (as percent)				1.00%
2012 ABL Revolver \| Revolving Credit Facility \| LIBOR \| Minimum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (as percent)				2.00%
2012 ABL Revolver \| Revolving Credit Facility \| LIBOR \| Maximum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (as percent)				2.25%
2012 ABL Revolver \| Revolving Credit Facility \| Base Rate \| Minimum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (as percent)				1.00%
2012 ABL Revolver \| Revolving Credit Facility \| Base Rate \| Maximum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (as percent)				1.25%
2012 ABL Revolver \| Revolving Credit Facility \| Federal Funds Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component (as percent)				0.50%
ABL Revolver Amendment 4 \| Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, term			5 years
2012 ABL Revolver, Amendment No. 3 \| Revolving Credit Facility
Debt Instrument [Line Items]
Revolving credit facility, increase in borrowing capacity				$ 40,000,000.0
ABL Amendment No. 5 \| Revolving Credit Facility
Debt Instrument [Line Items]
Debt Instrument, temporary suspension of financial reporting covenant, period		60 days
2012 ABL Revolver, Amendment No. 6 \| Revolving Credit Facility
Debt Instrument [Line Items]
Revolving credit facility, increase in borrowing capacity									$ 40,000,000.0
Term Loans \| 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount						$ 660,000,000.0
Debt instrument, term						7 years
Debt instrument, discount (as percent)						1.50%
Proceeds from issuance of long-term debt						$ 650,100,000
Term Loans \| 2012 Term Loan, Amendment No. 1 \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)					2.75%
Debt instrument, reference rate floor (as percent)					1.00%
Term Loans \| 2012 Term Loan, Amendment No. 1 \| Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (as percent)					2.00%
Term Loans \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, reference rate floor (as percent)				1.00%
Term Loans \| 2012 Term Loan, Amendment No. 2 \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)				3.125%
Term Loans \| 2012 Term Loan, Amendment No. 2 \| Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (as percent)				2.00%
Term Loans \| 2012 Senior Notes \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)							2.00%
Term Loans \| 2012 Senior Notes \| Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)							1.00%
Term Loans \| Term B-5 Loans \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)	2.00%
Debt instrument, reference rate floor (as percent)	0.00%
Term Loans \| Term B-5 Loans \| Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)	1.00%
Debt instrument, reference rate floor (as percent)	1.00%
2012 Term B-3 Loan \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, face amount										$ 852,500,000.0
2012 Term B-1 Loan \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, face amount										207,500,000.0
2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, face amount				$ 720,000,000.0
2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 2 \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)				3.50%
Debt instrument, reference rate floor (as percent)				1.00%
2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 2 \| Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (as percent)				2.00%
Interest rate, contingent margin step-down per annum (as percent)				3.25%
2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, face amount										$ 645,000,000.0
2012 Term B-4 Loans \| 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount									$ 1,427,000,000.0
Debt instrument, average interest rate (as percent)							4.50%

Long-Term Debt (Narrative 2013 Senior Notes) (Details) - Senior Notes - 2013 Senior Notes - USD ($)	Mar. 31, 2018	Dec. 17, 2013
Debt Instrument [Line Items]
Debt instrument, face amount		$ 400,000,000.0
Debt instrument, stated interest rate (as percent)	5.375%	5.375%

Long-Term Debt (Narrative 2016 Senior Notes) (Details) - Senior Notes - 2016 Senior Notes - USD ($)	Mar. 21, 2018	Mar. 31, 2018	Feb. 19, 2016
Debt Instrument [Line Items]
Debt instrument, face amount	$ 250,000,000.0		$ 350,000,000.0
Debt instrument, stated interest rate (as percent)	6.375%	6.375%	6.375%
Issuance price (as percent)	101.00%

Long-Term Debt (Narrative Redemptions and Restrictions) (Details) - USD ($) $ in Thousands		12 Months Ended
	Feb. 19, 2016	Mar. 31, 2018	Mar. 31, 2017
Debt Instrument [Line Items]
Unamortized debt costs		$ 20,048	$ 28,268
Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Unamortized debt costs		1,100	1,300
Repayments of long-term debt		75,000
Revolving credit facility, remaining borrowing capacity		$ 96,600
Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount (as percent)		101.00%
Unamortized debt costs		$ 5,000	4,600
Senior Notes \| 2016 Senior Notes
Debt Instrument [Line Items]
Unamortized debt costs		$ 3,700	4,900
Senior Notes \| Indirect guarantee of indebtedness \| 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount (as percent)	101.00%
Senior Notes \| Prior to December 15, 2016 \| 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, percentage of principal amount which can be redeemed (as percent)		35.00%
Debt instrument, redemption price, percentage of principal amount, using proceeds of equity offerings (as percent)		105.375%
Senior Notes \| Prior to March 1, 2019 \| 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, percentage of principal amount which can be redeemed (as percent)	40.00%
Debt instrument, redemption price, percentage of principal amount (as percent)	100.00%
Term Loans \| 2012 Term Loan
Debt Instrument [Line Items]
Unamortized debt costs		$ 11,300	$ 18,800

Long-Term Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 21, 2018	Mar. 31, 2017	Feb. 19, 2016	Dec. 17, 2013
Debt Instrument [Line Items]
Long-term debt, gross	$ 2,013,000		$ 2,222,000
Current portion of long-term debt	0		0
Long-term debt, gross, excluding current maturities	2,013,000		2,222,000
Less unamortized debt costs	(20,048)		(28,268)
Long-term debt, net	1,992,952		2,193,732
2016 Senior Notes \| Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	600,000		350,000
Less unamortized debt costs	$ (3,700)		(4,900)
Debt instrument, stated interest rate (as percent)	6.375%	6.375%		6.375%
2013 Senior Notes \| Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	$ 400,000		400,000
Less unamortized debt costs	$ (5,000)		(4,600)
Debt instrument, stated interest rate (as percent)	5.375%				5.375%
2012 Senior Notes \| Term Loans
Debt Instrument [Line Items]
Long-term debt, gross	$ 938,000		1,382,000
2012 Senior Notes \| Term Loans \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)	2.00%
Debt instrument, variable rate, minimum	0.00%
2012 Senior Notes \| Term Loans \| Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (as percent)	1.00%
Debt instrument, variable rate, minimum	1.00%
2012 ABL Revolver \| Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt, gross	$ 75,000		90,000
Less unamortized debt costs	$ (1,100)		$ (1,300)

Long-Term Debt (Maturities of Long-term Debt) (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Debt Disclosure [Abstract]
2019	$ 0
2020	0
2021	0
2022	477,000
2023	9,750
Thereafter	1,526,250
Long-term debt, gross	$ 2,013,000	$ 2,222,000

Fair Value Measurements (Summary of Carrying Amounts and Estimated Fair Value) (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Senior Notes \| 2016 Senior Notes \| Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	$ 600,000	$ 350,000
Senior Notes \| 2016 Senior Notes \| Fair value \| Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	610,500	367,500
Senior Notes \| 2013 Senior Notes \| Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	400,000	400,000
Senior Notes \| 2013 Senior Notes \| Fair value \| Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	402,000	409,000
Term Loans \| 2012 Term B-5 Loans \| Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	938,000	1,382,000
Term Loans \| 2012 Term B-5 Loans \| Fair value \| Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	939,173	1,395,820
Revolving Credit Facility \| 2012 ABL Revolver \| Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of credit, fair value disclosure	75,000	90,000
Revolving Credit Facility \| 2012 ABL Revolver \| Fair value \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of credit, fair value disclosure	$ 75,000	$ 90,000

Stockholders' Equity (Narrative) (Details)	12 Months Ended
Stockholders' Equity (Narrative) (Details)	Mar. 31, 2018 USD ($) vote / shares $ / shares shares	Mar. 31, 2017 $ / shares shares
Class of Stock [Line Items]
Common stock, shares authorized (in shares) \| shares	250,000,000	250,000,000
Common stock, par value (in USD per share) \| $ / shares	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares) \| shares	5,000,000	5,000,000
Preferred stock, par value (in USD per share) \| $ / shares	$ 0.01	$ 0.01
Voting rights, number of votes per common share owned \| vote / shares	1
Dividends declared on common stock \| $	$ 0
Restricted Shares
Class of Stock [Line Items]
Restricted stock repurchased during period (in shares) \| shares	20,549	25,768
Restricted stock acquired, average cost per share (in USD per share) \| $ / shares	$ 52.33	$ 55.51

Share-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended	12 Months Ended
	Aug. 01, 2017	May 08, 2017	May 31, 2014	Jun. 30, 2014	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase to plan term				10 years
Stock-based compensation costs					$ 8,909	$ 8,148	$ 9,954
Tax benefit recognized from share-based compensation expense					1,800	2,600	3,500
Share-based compensation expense, not yet recognized					$ 8,200
Share-based compensation expense, not yet recognized, period for recognition					9 months 18 days
Total fair value of shares vested					$ 6,800	6,000	7,000
Proceeds from exercise of stock options					1,620	4,028	6,689
Income tax benefit realized from exercise of stock awards					$ 1,100	$ 2,000	$ 3,600
Number of shares available for issuance under plan (in shares)					2,200,000
Options granted (in shares)					182,800	264,300	208,200
Options exercised, intrinsic value					$ 1,200	$ 3,200	$ 8,600
Performance Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock units granted in period (in shares)		35,593
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock units granted in period (in shares)	2,564	54,773			105,800	68,400	266,100
Options granted (in shares)	1
Award vesting period					3 years
Period following director's term In which stock awards may be settled					6 months
Granted, weighted-average grant-date fair value (in USD per share)					$ 55.61	$ 55.44	$ 42.41
Restricted Stock Units (RSUs) \| Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period					3 years
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)	1	182,823
Period following director's term In which stock awards may be settled					6 months
Award exercisability period, from date of grant (not greater than)					10 years
Granted, weighted-average grant-date fair value (in USD per share)					$ 21.20	$ 21.75	$ 17.24
Stock Options \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period					3 years
Stock Options \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period					5 years
2005 Long-term Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for grant (in shares)					5,000,000.0
Number of additional shares authorized under plan (in shares)				1,800,000.0
Maximum number of shares awarded, per employee, annual (in shares)			1,000,000	2,500,000.0

Share-Based Compensation (Restricted Shares Activity) (Details) - Restricted Stock Units (RSUs) - $ / shares			12 Months Ended
	Aug. 01, 2017	May 08, 2017	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Shares
Outstanding, beginning of period (in shares)			350,100	467,800	362,300
Granted (in shares)	2,564	54,773	105,800	68,400	266,100
Vested and issued (in shares)			(53,300)	(94,700)	(155,600)
Forfeited (in shares)			(9,100)	(91,400)	(5,000)
Outstanding, end of period (in shares)			393,500	350,100	467,800
Vested, end of period (in shares)			90,500	63,400	69,800
Weighted-Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)			$ 39.29	$ 35.22	$ 22.74
Granted, weighted-average grant-date fair value (in USD per share)			55.61	55.44	42.41
Vested and issued, weighted-average grant-date fair value (in USD per share)			34.30	28.51	18.31
Forfeited, weighted-average grant-date fair value (in USD per share)			48.76	41.71	39.61
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)			44.13	39.29	35.22
Vested, end of period, weighted-average grant-date fair value (in USD per share)			$ 29.88	$ 20.12	$ 14.76

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) - Stock Options - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	35.20%	37.80%	40.20%
Expected dividends	$ 0	$ 0	$ 0
Expected term in years	6 years	6 years	6 years
Risk-free rate	2.20%	1.70%	1.70%

Share-Based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Shares
Outstanding, beginning of period (in shares)	772,300	727,700	871,200
Granted (in shares)	182,800	264,300	208,200
Exercised (in shares)	(55,700)	(126,800)	(348,000)
Forfeited or expired (in shares)	(26,200)	(92,900)	(3,700)
Outstanding, end of period (in shares)	873,200	772,300	727,700
Exercisable, end of period (in shares)	495,000
Weighted-Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 37.70	$ 30.70	$ 23.40
Options, grant date fair value (in USD per share)	56.11	55.86	42.13
Exercised, weighted-average exercise price (in USD per share)	29.08	31.75	19.22
Forfeited or expired, weighted-average exercise price (in USD per share)	48.19	42.66	35.72
Outstanding, end of period, weighted-average exercise price (in USD per share)	41.79	$ 37.70	$ 30.70
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 32.41
Options
Outstanding, end of period, weighted-average remaining contractual term	7 years
Exercisable, end of period, weighted-average remaining contractual term	5 years 9 months 18 days
Outstanding, end of period, aggregate intrinsic value	$ 2,985
Exercisable, end of period, aggregate intrinsic value	$ 2,985

Accumulated Other Comprehensive Loss (Components of AOCI) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of Accumulated Other Comprehensive Loss	$ 1,178,610	$ 822,549	$ 744,336	$ 627,624
Reclassification from AOCI	0	0
Accumulated other comprehensive loss, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of Accumulated Other Comprehensive Loss	(19,315)	(26,352)	$ (23,525)	$ (23,412)
Cumulative translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of Accumulated Other Comprehensive Loss	(20,398)	(26,100)
Unrecognized net gain (loss) on pension plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of Accumulated Other Comprehensive Loss	$ 1,083	$ (252)

Employee Retirement Plans (Narrative) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, minimum annual contributions per participating employee (as percent)	1.00%
Defined contribution plan, maximum annual contributions per employee (as percent)	70.00%
Defined contribution plan, cost recognized	$ 100,000
Defined benefit obligation	61,882,000	$ 61,714,000	$ 61,187,000
Net periodic benefit cost (income) (less than $1.0 million)	(372,000)	(6,000)
Funded (unfunded) status at end of year	$ (11,374,000)	$ (13,942,000)
Expected return on plan assets, net of administrative fees (as percent)	6.25%	6.25%
Qualified plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Funded (unfunded) status at end of year	$ 0	$ 6,000,000
Unfunded plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit obligation	$ 5,900,000	$ 6,000,000
Fleet Employees Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, minimum annual contributions per participating employee (as percent)	2.00%
Defined contribution plan, maximum annual contributions per employee (as percent)	50.00%
Defined contribution plan, employer matching contribution, percent of match (as percent)	100.00%
Defined contribution plan, employer matching contribution, percent of employees pay (as percent)	6.00%
Defined contribution plan, cost recognized	$ 800,000
Contribution Tranche One
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, employer matching contribution, percent of match (as percent)	100.00%
Defined contribution plan, employer matching contribution, percent of employees pay (as percent)	3.00%
Contribution Tranche Two
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, employer matching contribution, percent of match (as percent)	50.00%
Defined contribution plan, employer matching contribution, percent of employees pay (as percent)	3.00%

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Net gain	$ 267,000
Net gain related to the lower blended tax rate	3,200
Net gain	270,200
Repatriation charge	1,900
Long-term deferred tax assets	1,000	$ 1,000
Valuation allowance	609	3,437
Decrease in valuation allowance	2,800
Unrecognized tax benefits	$ 10,827	$ 3,651	$ 4,084	$ 3,420
Effective income tax rate, change in enacted tax rate	10.10%	3.30%	2.60%

Employee Retirement Plans (Periodic Service Costs) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Change in benefit obligation:
Projected benefit obligation at beginning of period	$ 61,714	$ 61,187
Interest cost	2,529	456
Actuarial loss	800	791
Benefits paid	(3,161)	(720)
Projected benefit obligations at end of year	61,882	61,714
Change in plan assets:
Fair value of plan assets at beginning of period	47,772	41,560
Actual return on plan assets	5,505	854
Employer contribution	392	6,078
Benefits paid	(3,161)	(720)
Fair value of plan assets at end of year	50,508	47,772
Funded status at end of year	$ (11,374)	$ (13,942)

Income Taxes (Income Before Continuing Operations) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Income from Continuing Operations before Income Taxes:
United States									$ 84,435	$ 93,582	$ 142,253
Foreign									22,651	17,268	14,932
Income before income taxes	$ (52,562)	$ 57,639	$ 49,321	$ 52,688	$ 18,802	$ 50,733	$ 50,228	$ (8,913)	$ 107,086	$ 110,850	$ 157,185

Employee Retirement Plans (Amounts Recognized in the Balance Sheet) (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Current liability	$ 461	$ 463
Long-term liability	10,913	13,479
Total	$ 11,374	$ 13,942

Income Taxes (Components of Provision for Income Taxes) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Current
Federal									$ 31,327	$ 40,183	$ 6,080
State									2,686	2,808	1,171
Foreign									5,588	4,242	3,905
Deferred
Federal									(270,796)	(5,421)	44,787
State									(1,240)	(163)	1,678
Foreign									(49)	(194)	(343)
Total (benefit) provision for income taxes	$ (12,875)	$ (257,154)	$ 18,616	$ 18,929	$ 7,712	$ 19,092	$ 18,033	$ (3,382)	$ (232,484)	$ 41,455	$ 57,278

Employee Retirement Plans (Expected Return on Plan Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Interest cost	$ 2,529	$ 456
Expected return on assets	(2,901)	(462)
Net periodic benefit cost (income)	$ (372)	$ (6)

Income Taxes (Components of Deferred Tax Balances) (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$ 2,806	$ 5,280
Inventory capitalization	1,176	1,881
Inventory reserves	540	1,880
Net operating loss carryforwards	609	609
State income taxes	10,154	17,727
Accrued liabilities	2,210	2,174
Accrued compensation	4,992	9,574
Stock compensation	5,038	5,790
Other	4,975	7,925
Total deferred tax assets	32,500	52,840
Deferred Tax Liabilities
Property, plant and equipment	(6,032)	(9,157)
Intangible assets	(467,388)	(754,322)
Total deferred tax liabilities	(473,420)	(763,479)
Net deferred tax liability before valuation allowance	(440,920)	(710,639)
Valuation allowance	(609)	(3,437)
Net deferred tax liability	$ (441,529)	$ (714,076)

Employee Retirement Plans (Expected Benefit Payments) (Details) $ in Thousands	Mar. 31, 2018 USD ($)
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
2019 (expectation) to participant benefits	$ 1,461
2019	3,314
2020	3,386
2021	3,463
2022	3,588
2023	3,674
2024-2028	$ 19,157

Income Taxes (Reconciliation of Effective Tax Rate) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income tax provision at statutory rate	$ 37,480	$ 38,798	$ 55,015
Income tax provision at statutory rate (as percent)	35.00%	35.00%	35.00%
Foreign tax benefit	$ (2,084)	$ (2,322)	$ (2,894)
Foreign tax benefit provision (as percent)	(1.90%)	(2.10%)	(1.80%)
State income taxes, net of federal income tax benefit	$ 1,414	$ 1,820	$ 3,284
State income taxes, net of federal income tax benefit (as percent)	1.30%	1.70%	2.00%
Impact of tax legislation	$ (268,244)	$ 0	$ 0
Impact of tax (as percent)	(250.50%)	0.00%	0.00%
Goodwill adjustment for sale of asset	$ 0	$ 3,208	$ 0
Goodwill adjustment for sale of asset (as percent)	0.00%	2.90%	0.00%
Nondeductible transaction costs	$ 0	$ 686	$ 1,071
Nondeductible transaction costs (as percent)	0.00%	0.60%	0.70%
Nondeductible compensation	$ 0	$ 342	$ 758
Nondeductible compensation (as percent)	0.00%	0.30%	0.50%
Other	$ (1,050)	$ (1,077)	$ 44
Other (as percent)	(1.00%)	(1.00%)	0.00%
Total (benefit) provision for income taxes	$ (232,484)	$ 41,455	$ 57,278
Total provision for income taxes (as percent)	(217.10%)	37.40%	36.40%

Employee Retirement Plans (Category of Plan Assets) (Details)	Mar. 31, 2018	Mar. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	100.00%
Percentage of Plan Assets	100.00%	100.00%
Domestic large cap equities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	21.00%
Percentage of Plan Assets	21.00%	41.00%
Domestic small/mid cap equities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	6.00%
Percentage of Plan Assets	6.00%	7.00%
International equities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	18.00%
Percentage of Plan Assets	18.00%	16.00%
Balanced/asset allocation
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	0.00%
Percentage of Plan Assets	0.00%	2.00%
Fixed income and cash
Defined Benefit Plan Disclosure [Line Items]
Target Allocation	55.00%
Percentage of Plan Assets	55.00%	34.00%

Income Taxes (Uncertain Tax Liability Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance – beginning of year	$ 3,651	$ 4,084	$ 3,420
Additions based on tax positions related to the current year	7,286	583	664
Reductions based on lapse of statute of limitations	(110)	(1,016)	0
Balance – end of year	$ 10,827	$ 3,651	$ 4,084

Employee Retirement Plans (Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Unrecognized actuarial loss	$ (1,407)				$ 399					$ (1,407)	$ 399
Unrecognized prior service credit	0				0					0	0
Net income	$ (39,687)	$ 314,793	$ 30,705	$ 33,759	$ 11,090	$ 31,641	$ 32,195	$ (5,531)		$ 339,570	$ 69,395	$ 99,907
Scenario, Forecast \| Unrecognized actuarial (loss) \| Reclassification out of Accumulated Other Comprehensive Income
Defined Benefit Plan Disclosure [Line Items]
Net income									$ 0
Scenario, Forecast \| Unrecognized prior service credit \| Reclassification out of Accumulated Other Comprehensive Income
Defined Benefit Plan Disclosure [Line Items]
Net income									$ 0

Employee Retirement Plans (Weighted Average Assumptions) (Details)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Expected return on plan assets, net of administrative fees	6.25%	6.25%
Rate of compensation increase	0.00%	0.00%
Minimum
Defined Benefit Plan Disclosure [Line Items]
Discount rate	3.93%	3.92%
Maximum
Defined Benefit Plan Disclosure [Line Items]
Discount rate	4.07%	4.21%

Commitments and Contingencies (Future Minimum Rental Payments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Operating Leased Assets [Line Items]
2019	$ 3,261
2020	2,823
2021	2,536
2022	2,187
2023	1,693
Thereafter	8,487
Total future minimum payments due	20,987	$ 10,982
Less: Sublease rentals	(1,018)	(690)
Minimum lease payments, net of sublease rentals	19,969	10,292
Operating leases, rent expense	1,900	$ 2,000	$ 1,800
Facilities
Operating Leased Assets [Line Items]
2019	2,928
2020	2,685
2021	2,505
2022	2,163
2023	1,683
Thereafter	8,487
Total future minimum payments due	20,451
Equipment
Operating Leased Assets [Line Items]
2019	333
2020	138
2021	31
2022	24
2023	10
Thereafter	0
Total future minimum payments due	$ 536

Commitments and Contingencies (Long-term Supply Agreement) (Details) - Third-party Manufacturing $ in Thousands	Mar. 31, 2018 USD ($)
Long-term Purchase Commitment [Line Items]
2019	$ 9,473
2020	9,839
2021	9,280
2022	9,280
2023	1,578
Thereafter	0
Total purchase commitment	$ 39,450

Concentrations of Risk (Narrative) (Details) - manufacturer	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Concentration Risk [Line Items]
Number of third-party manufacturers	116
Sales \| Product concentration risk \| Top 5 customers
Concentration Risk [Line Items]
Concentration risk, percentage	41.20%	40.00%	41.90%
Sales \| Customer concentration risk \| Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	23.80%	21.10%	20.20%
Sales \| Supplier concentration risk
Concentration Risk [Line Items]
Concentration risk, percentage	73.60%	78.40%
Number of third-party manufacturers with long-term contracts	46	47
Accounts receivable \| Customer concentration risk \| Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	26.10%

Business Segments (Information on Operating and Reportable Segments) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information, Profit (Loss):
Total revenues	$ 255,965	$ 270,615	$ 258,026	$ 256,573	$ 240,670	$ 216,763	$ 215,052	$ 209,575	$ 1,041,179	$ 882,060	$ 806,247
Tradename impairment	99,924	0	0	0					99,924	0	0
Cost of sales	114,708	122,941	113,928	113,097	110,487	92,216	91,087	87,984	464,674	381,774	339,036
Gross profit	141,257	147,674	144,098	143,476	130,183	124,547	123,965	121,591	576,505	500,286	467,211
Advertising and promotion	35,319	35,835	39,188	36,944	41,450	30,682	28,592	27,635	147,286	128,359	110,802
Contribution margin									429,219	371,927	356,409
Other operating expenses									213,353	166,314	96,094
Operating income	(22,823)	83,503	76,157	79,029	53,054	69,287	71,058	12,214	215,866	205,613	260,315
Other expense									108,780	94,763	103,130
Income before income taxes	(52,562)	57,639	49,321	52,688	18,802	50,733	50,228	(8,913)	107,086	110,850	157,185
(Benefit) provision for income taxes	(12,875)	(257,154)	18,616	18,929	7,712	19,092	18,033	(3,382)	(232,484)	41,455	57,278
Net income	$ (39,687)	$ 314,793	$ 30,705	$ 33,759	11,090	31,641	32,195	(5,531)	339,570	69,395	99,907
Loss on divestitures and sales of property and equipment					$ 268	$ (3,405)	$ (496)	$ 55,453	0	51,820	0
Intangible assets, tradename impairment									99,924
Disposal held for sale \| Pediacare, New Skin, Fiber Choice, EPT, Dermoplast, and Comet
Segment Reporting Information, Profit (Loss):
Loss on divestitures and sales of property and equipment										51,800
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues									868,874	720,824	657,871
Cost of sales									357,298	282,750	250,018
Gross profit									511,576	438,074	407,853
Advertising and promotion									129,058	112,465	97,393
Contribution margin									382,518	325,609	310,460
North American OTC Healthcare \| Intersegment Eliminations
Segment Reporting Information, Profit (Loss):
Total revenues									(7,700)	(4,200)	(2,700)
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues									91,658	73,304	57,713
Cost of sales									40,244	30,789	21,676
Gross profit									51,414	42,515	36,037
Advertising and promotion									16,267	13,434	11,114
Contribution margin									35,147	29,081	24,923
Household Cleaning
Segment Reporting Information, Profit (Loss):
Total revenues									80,647	87,932	90,663
Cost of sales									67,132	68,235	67,342
Gross profit									13,515	19,697	23,321
Advertising and promotion									1,961	2,460	2,295
Contribution margin									$ 11,554	$ 17,237	$ 21,026

Business Segments (Revenue by Product) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Revenue from External Customer [Line Items]
Total revenues	$ 255,965	$ 270,615	$ 258,026	$ 256,573	$ 240,670	$ 216,763	$ 215,052	$ 209,575	$ 1,041,179	$ 882,060	$ 806,247
Analgesics
Revenue from External Customer [Line Items]
Total revenues									119,417	122,175	119,465
Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									111,847	108,785	116,570
Women's Health
Revenue from External Customer [Line Items]
Total revenues									259,384	150,882	135,166
Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									152,236	101,312	94,587
Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									104,052	109,693	107,498
Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									96,888	87,353	85,074
Oral Care
Revenue from External Customer [Line Items]
Total revenues									111,002	108,099	51,125
Other OTC
Revenue from External Customer [Line Items]
Total revenues									5,706	5,829	6,099
Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									80,647	87,932	90,663
North American OTC Healthcare
Revenue from External Customer [Line Items]
Total revenues									868,874	720,824	657,871
North American OTC Healthcare \| Analgesics
Revenue from External Customer [Line Items]
Total revenues									118,610	120,253	117,337
North American OTC Healthcare \| Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									93,537	90,795	100,148
North American OTC Healthcare \| Women's Health
Revenue from External Customer [Line Items]
Total revenues									247,244	147,071	132,184
North American OTC Healthcare \| Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									117,627	76,500	74,568
North American OTC Healthcare \| Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									92,308	97,618	95,515
North American OTC Healthcare \| Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									94,775	85,194	82,941
North American OTC Healthcare \| Oral Care
Revenue from External Customer [Line Items]
Total revenues									99,072	97,586	49,099
North American OTC Healthcare \| Other OTC
Revenue from External Customer [Line Items]
Total revenues									5,701	5,807	6,079
International OTC Healthcare
Revenue from External Customer [Line Items]
Total revenues									91,658	73,304	57,713
International OTC Healthcare \| Analgesics
Revenue from External Customer [Line Items]
Total revenues									807	1,922	2,128
International OTC Healthcare \| Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									18,310	17,990	16,422
International OTC Healthcare \| Women's Health
Revenue from External Customer [Line Items]
Total revenues									12,140	3,811	2,982
International OTC Healthcare \| Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									34,609	24,812	20,019
International OTC Healthcare \| Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									11,744	12,075	11,983
International OTC Healthcare \| Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									2,113	2,159	2,133
International OTC Healthcare \| Oral Care
Revenue from External Customer [Line Items]
Total revenues									11,930	10,513	2,026
International OTC Healthcare \| Other OTC
Revenue from External Customer [Line Items]
Total revenues									5	22	20
Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									80,647	87,932	90,663
Household Cleaning \| Analgesics
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Women's Health
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Oral Care
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Other OTC
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									$ 80,647	$ 87,932	$ 90,663

Business Segments (Revenue by Geographic Area) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 255,965	$ 270,615	$ 258,026	$ 256,573	$ 240,670	$ 216,763	$ 215,052	$ 209,575	$ 1,041,179	$ 882,060	$ 806,247
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues									903,511	769,732	704,360
Rest of world
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues									$ 137,668	$ 112,328	$ 101,887

Business Segments (Assets by Segment) (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 620,098	$ 615,252	$ 360,191
Indefinite-lived intangible assets	2,490,303	2,589,155
Finite-lived intangible assets	290,613	314,458
Intangible assets, net (excluding goodwill)	2,780,916	2,903,613
Intangible assets, net (including goodwill)	3,401,014	3,518,865
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	580,934	576,453	330,615
Intangible assets, net (excluding goodwill)	2,641,092	2,691,392
Intangible assets, net (including goodwill)	3,222,026	3,267,845
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	32,919	32,554	22,776
Intangible assets, net (excluding goodwill)	90,074	90,026
Intangible assets, net (including goodwill)	122,993	122,580
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	6,245	6,245	$ 6,800
Intangible assets, net (excluding goodwill)	49,750	122,195
Intangible assets, net (including goodwill)	$ 55,995	$ 128,440

Business Segments (Goodwill and Intangible Assets by Geographic Area) (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Schedule of Goodwill and Intangible Assets by Geographic Areas [Line Items]
Intangible assets, net (including goodwill)	$ 3,401,014	$ 3,518,865
United States
Schedule of Goodwill and Intangible Assets by Geographic Areas [Line Items]
Intangible assets, net (including goodwill)	3,278,021	3,396,285
Rest of world
Schedule of Goodwill and Intangible Assets by Geographic Areas [Line Items]
Intangible assets, net (including goodwill)	$ 122,993	$ 122,580

Unaudited Quarterly Financial Information (Schedule of Quarterly Financial Information) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Total revenues	$ 255,965	$ 270,615	$ 258,026	$ 256,573	$ 240,670	$ 216,763	$ 215,052	$ 209,575	$ 1,041,179	$ 882,060	$ 806,247
Cost of sales	114,708	122,941	113,928	113,097	110,487	92,216	91,087	87,984	464,674	381,774	339,036
Gross profit	141,257	147,674	144,098	143,476	130,183	124,547	123,965	121,591	576,505	500,286	467,211
Operating Expenses
Advertising and promotion	35,319	35,835	39,188	36,944	41,450	30,682	28,592	27,635	147,286	128,359	110,802
General and administrative	21,891	21,207	21,567	20,336	28,760	22,131	18,795	19,457	85,001	89,143	72,418
Depreciation and amortization	6,946	7,129	7,186	7,167	6,651	5,852	6,016	6,832	28,428	25,351	23,676
Loss on divestitures					268	(3,405)	(496)	55,453	0	51,820	0
Tradename impairment	99,924	0	0	0					99,924	0	0
Total operating expenses	164,080	64,171	67,941	64,447	77,129	55,260	52,907	109,377	360,639	294,673	206,896
Operating income	(22,823)	83,503	76,157	79,029	53,054	69,287	71,058	12,214	215,866	205,613	260,315
Net interest expense	26,838	25,864	26,836	26,341	32,832	18,554	20,830	21,127
Loss on extinguishment of debt	2,901	0	0	0	1,420	0	0	0	2,901	1,420	17,970
Income before income taxes	(52,562)	57,639	49,321	52,688	18,802	50,733	50,228	(8,913)	107,086	110,850	157,185
Provision (benefit) for income taxes	(12,875)	(257,154)	18,616	18,929	7,712	19,092	18,033	(3,382)	(232,484)	41,455	57,278
Net income	$ (39,687)	$ 314,793	$ 30,705	$ 33,759	$ 11,090	$ 31,641	$ 32,195	$ (5,531)	$ 339,570	$ 69,395	$ 99,907
Earnings (loss) per share:
Basic (in USD per share)	$ (0.75)	$ 5.93	$ 0.58	$ 0.64	$ 0.21	$ 0.60	$ 0.61	$ (0.10)	$ 6.40	$ 1.31	$ 1.89
Diluted (in USD per share)	$ (0.75)	$ 5.88	$ 0.57	$ 0.63	$ 0.21	$ 0.59	$ 0.60	$ (0.10)	$ 6.34	$ 1.30	$ 1.88
Weighted average shares outstanding:
Basic (in shares)	53,131	53,129	53,098	53,038	53,009	52,999	52,993	52,881	53,099	52,976	52,754
Diluted (in shares)	53,131	53,543	53,539	53,509	53,419	53,359	53,345	52,881	53,526	53,362	53,143
Comprehensive income (loss), net of tax:
Currency translation adjustments	$ (2,625)	$ 4,492	$ 2,716	$ 1,119	$ 9,282	$ (8,736)	$ 2,703	$ (5,824)	$ 5,702	$ (2,575)	$ (113)
Unrecognized net gain (loss) on pension plans	1,334	0	0	1	(252)	0	0	0	(1,335)	252	0
Total other comprehensive income (loss)	(1,291)	4,492	2,716	1,120	9,030	(8,736)	2,703	(5,824)	7,037	(2,827)	(113)
Comprehensive (loss) income	$ (40,978)	$ 319,285	$ 33,421	$ 34,879	$ 20,120	$ 22,905	$ 34,898	$ (11,355)	$ 346,607	$ 66,568	$ 99,794

Subsequent Events (Narrative) (Details) - USD ($)				12 Months Ended
Subsequent Events (Narrative) (Details) - USD ($)	May 07, 2018	Aug. 01, 2017	May 08, 2017	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	May 10, 2018
Subsequent Event [Line Items]
Options, grant date fair value (in USD per share)				$ 56.11	$ 55.86	$ 42.13
Options granted (in shares)				182,800	264,300	208,200
Performance Units
Subsequent Event [Line Items]
Common stock units granted in period (in shares)			35,593
Restricted Stock Units (RSUs)
Subsequent Event [Line Items]
Common stock units granted in period (in shares)		2,564	54,773	105,800	68,400	266,100
Options granted (in shares)		1
Award vesting period				3 years
Stock Options
Subsequent Event [Line Items]
Options granted (in shares)		1	182,823
Subsequent Event
Subsequent Event [Line Items]
Shares authorized for repurchase							$ 50,000,000.0
Options, grant date fair value (in USD per share)	$ 29.46
Subsequent Event \| Performance Units
Subsequent Event [Line Items]
Common stock units granted in period (in shares)	103,406
Award vesting period	3 years
Subsequent Event \| Restricted Stock Units (RSUs)
Subsequent Event [Line Items]
Vesting rights (as percent)	33.30%
Common stock units granted in period (in shares)	100,399
Award vesting period	3 years
Subsequent Event \| Stock Options
Subsequent Event [Line Items]
Expiration period	10 years
Vesting rights (as percent)	33.30%
Options granted (in shares)	294,484
Award vesting period	3 years

Schedule II Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Reserves for sales returns and allowance
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	$ 9,429	$ 8,823	$ 6,716
Amounts charged to expense	62,953	41,173	41,217
Deductions	(63,569)	(41,417)	(40,085)
Other	0	850	975
Valuation allowances and reserves, balance at end of year	8,813	9,429	8,823
Reserves for trade promotions
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	15,193	12,641	9,932
Amounts charged to expense	78,669	69,475	62,331
Deductions	(82,427)	(69,713)	(62,409)
Other	0	2,790	2,787
Valuation allowances and reserves, balance at end of year	11,435	15,193	12,641
Reserves for consumer coupon redemptions
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	4,614	4,323	1,672
Amounts charged to expense	7,283	7,616	6,235
Deductions	(9,252)	(7,745)	(5,637)
Other	0	420	2,053
Valuation allowances and reserves, balance at end of year	2,645	4,614	4,323
Allowance for doubtful accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	1,352	815	1,277
Amounts charged to expense	187	177	(276)
Deductions	(336)	360	(186)
Other	0	0	0
Valuation allowances and reserves, balance at end of year	1,203	1,352	815
Deferred tax valuation allowance
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	3,437	0
Amounts charged to expense	0	0
Deductions	0	0
Other	(2,828)	3,437
Valuation allowances and reserves, balance at end of year	$ 609	$ 3,437	$ 0

Business and Basis of Presentation (Intangible Assets) (Details)	12 Months Ended
	Mar. 31, 2018
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	30 years